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! ~~6 ABSTRACT 
1. The pharmacokinetics of morphine have been measured in 
four patients with renal failure and three healthy 
volunteers following intramuscular administration of 
papaveretum. Morphine blood levels were determined 
using GCMS with specif ion monitoring. The 
significantly shorter drug elimination half-life found 
for the patients suggests that renal failure does not 
impair the elimination of morphine. 
2. A CI GCMS assay with specific ion monitoring has been 
developed for measuring the anti parkinsonian drug 
benztropine in post-mortem specimens. The assay is 
potentially more sensitive than a similar assay using 
electron impact ionisation. 
3. The level of atropine in an aqueous extract of Datura 
stramonium has been measured by GCMS with selected ion 
monitoring. The results show that such an extract 
will contain most the atropine present in the plant 
material. The levels are such that several medium-
sized glassfuls will contain sufficient atropine to 
constitute a dangerous drug dose. 
4. A Hewlett-Packard 5982A GCMS has been successfully 
modified to allow it to be used to record in-beam 
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mass with a commercially available DCI probe. 
The effectiveness of these modifications is discussed 
and mass spectra of some physiologically 
active compounds are presented. 
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CHAPTER 1 
INTRODUCTION 
1.1 Drug Analysis By Mass Spectrometry 
1 
Mass spectrometry is a powerful instrumental method for 
chemical analysis. The information contained in a single 
mass spectrum, recorded using very small amounts of sample, 
will often allow the unambiguous identification or 
structural elucidation of an unknown compound. The 
development of ionisation techniques which remove the 
requirement that the sample be vaporised be~ore ionisation 
has made a whole range of compounds of biomedical and 
biochemical importance amenable to mass spectrometric 
analysis. 
The high sensi vity and specificity of the mass 
spectrometer are enhanced by using a gas chromatograph as 
the mass spectrometer inlet, and" combined gas 
chromatography-mass spectrometry (GCMS) is one of the most 
powerful analytical techniques available today. The 
combination of the very high sensitivity and specificity of 
GCMS is unobtainable even with highly sensitive 
immunological techniques. A number of major developments 
have occurred in recent years in GCMS methodology. These 
include the direct coupling ot capillary gas chromatographic 
columns to mass spectrometers, the widespread availability 
of ion sources for chemical ionisation, and the increasing 
use of isotopically labelled internal standards in assays 
using quantitative selected ion monitoring (QSIM). 
Capillary columns offer two main advantages over packed 
columns. An assay sensitivity is greatly increased by using 
a capillary column, and separations of components in a 
complex mixture that were previously unobtainable with 
packed columns can often be performed almost routinely. 
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Chemical ionisation (CI), although it has some disadvantages, is 
well suited for many analyses. The intense peaks usually 
seen in the molecular ion region of a Cl spectrum will 
often allow rapid identification of an unknown compound. 
The ions producing these peaks can also be monitored in a Cl 
QSlM assay for the compound, often giving greater 
sensitivity and specificity than is possible in a similar 
assay using electron impact (El) ionisation. Stable 
isotopically-labelled analogues of compounds to be measured 
come closest to meeting the characteristics of ideal 
internal standards. These compounds behave almost 
identically to the analyte throughout the extraction, 
chromatographic separation and ionisation processes, so that 
the weight ratio of the added internal standard to analyte 
will remain unaffected by any of these operations. 
This thesis is concerned with drug analysis by mass 
spectrometry. The detection and identification of drugs and 
their metabolites, often at very low levels in a complex 
biological matrix such as blood, can be a very difficult and 
demanding task. Mass spectrometry is often the only 
analytical method with the necessary sensitivity and 
specificity to unambiguously identify and then measure the 
analyte. The first three sections of this thesis describe 
the application of GCMS facilities available in the 
Chemistry Department at the University of Canterbury to 
three specific drug-related problems. The first section 
describes a study of morphine pharmacokinetics in patients 
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with renal failure. Plasma morphine concentrations in four 
patients with renal failure and in three healthy volunteers 
were measured using CI QSIM, and morphine pharmacokinetics 
in the two groups compared. The second on describes 
the development of a CI QSIM assay for measuring the 
anti parkinsonian drug benztropine in post-mortem specimens. 
This assay was developed for use by a nearby Government 
laboratory which had reported difficulties in detecting this 
drug. The third section describes the measurement of the 
atropine concentration in an aqueous extract prepared from 
the Solanaceous plant Datura stramonium. There is an 
increasing incidence of intoxication and poisoning following 
abuse of preparations from this plant and was of interest 
to determine level of atropine likely to be present in 
aqueous Datura stramonium extracts. 
The fourth and final section of the thesis is concerned 
with drug analysis by mass spectrometry using a heated 
probe. There are a significant number of biochemically 
important compounds which are not sufficiently volatile or 
which are too thermally labile to be analysed using a, 
conventional heated solids probe. Desorption chemical 
ionisation (DCI) and desorption electron ionisation (DEI) 
are two simi techniques which have recently been 
developed for obtaining spectra of such compounds. This 
section describes modifications made to a quadrupole mass 
spectrometer to allow it to be used with a commercially 
available DCI probe. 
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1.2 The HP5982A GCMS 
The work described in this thesis was carried out using 
a Hewlett-Packard 5982A GCMS. This is a quadrupole 
instrument with an ion source that can be configured for 
either EI or CI operation. Reconfiguring the source 
physically changes the ion chamber and can be accomplished 
without breaking the source vacuum. The mass filter is 
actually a "dodecapole " because it has four pairs of tunable 
electrodes or "blades" between the cylindrical quadrupole 
rods (Figure 1). These blades modify the electric f Id 
produced by the radio frequency and direct current voltages 
applied to the rods so that it approximates the f Id which 
would be generated by an hyperbo c rod assembly. The mass 
spectrometer is pumped differentially by two high capacity 
oil diffusion pumps. Each diffusion pump is backed by a 
mechanical rotary pump. Samples are admitted to the mass 
spectrometer via two gas chromatographic column inlets, or 
through a direct insertion probe (DIP) let using a batch 
inlet probe or a heated solids probe. The CI reagent gas is 
admitted through the DIP inlet, or through the 
chromatographic column inlets when it is the GC carrier gas. 
Mass spectra can be recorded over the mass range 3-1000 
atomic mass units, or up to four separate ions monitored 
using a multiple ion detector. Spectra are recorded with a 
light-beam oscillograph on light sensitive chart paper, and 
selected ion chromatograms are recorded with a conventional 
chart recorder connected to the multiple ion detector. A 
block diagram of the instrument is presented in Figure 2. 
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Figure 2. Block diagram of the HP5892A GCMS 
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Several substant 1 modifications were made to the 
HP5982A GCMS used for the work described in this thesis. 
These changes were largely to the mass spectrometer ion 
source. To aid in describing these modifications in later 
sec ons a detailed description of the original ion source 
is given here. 
Exploded-view scale drawings of the ion source are 
presented in Figures 33 to 35. The source proper is housed 
inside a gold plated shroud (1) containing the source 
heater, which is controlled by a thermocouple (2), and two 
electron beam collimating magnets (3). Attached to the 
shroud is the entrance lens (4) which injects ions from the 
source into the quadrupole mass analyser. The EI ion 
chamber is a circular cavity in the ion chamber body (5) to 
which is attached the electron filament assembly (6) and the 
electron trap assembly (7). The ion chamber has four 
apertures, one each for the electron beam entrance, the 
electron beam exit, the inlet for the first GC column, and a 
combined DIP inlet and inlet for the second GC column. The 
GC column effluents are delivered to their respective inlets 
via glass-lined stainless steel tubes (8), and DIP which 
is introduced into the source via the solids probe insertion 
lock is correctly positioned near the ion chamber by the DIP 
sleeve (9). The plunger assembly (10), mounted on a support 
shaft (11) and held in position by a screw (12), houses the 
CI ion chamber. The chamber is formed by the repeller (13), 
the ion exit (14) and a spacer (15). These components are 
electrically insulated from the plunger body by two ceramic 
insulators (16) and are held in position by a lock ring 
(17). A needle assembly (18) makes electrical contact with 
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both the ller and the ion exit but is otherwise 
insulated from the plunger and other source parts. The 
spacer (15) of the plunger assembly has three apertures 
which are coincident with three similar apertures in the 
plunger body. These function as the electron entrance, the 
inlet for the first GC column, and the combined DIP inlet 
and inlet for the second GC column when the source is 
configured for CIa The plunger assembly can be moved into 
or out of the EI ion chamber by movement of the support 
shaft (11). This shaft passes through the end flange (19) 
of the ion source housing and is moved by a lever mechanism. 
A stainless-steel bellows maintains the seal between 
atmosphere and the ion source interior during plunger 
movement. 
The two ion source configurations are depicted 
schematically in Figure 36. In the EI configuration the 
plunger is withdrawn to the left of the ion chamber body. 
Sample molecules are admitted to the EI ion chamber via the 
GC column inlet or the combined DIP and GC column inlet and 
ions are formed by impact with a beam of thermally emitted 
electrons travelling perpendicular to the mass analyser 
axis. The filament current is regulated to give a constant 
electron trap current, as is usual practice, ensuring 
constant electron flux in the ion chamber. The ion exit 
(14) of the CI ion chamber functions as an ion repeller 
electrode to aid extraction of positively charged ions from 
the source. The necessary electrical potential on this 
electrode is applied via the needle assembly. To change 
from the EI to the CI configuration the plunger is moved 
inside the EI ion chamber until the electron entrance and 
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sample inlet (both GC column, and combined DIP and GC 
column) apertures of both ion chambers are coincident. The 
needle assembly now contacts only the repeller (13) and 
blocks the hole in it. During CI operation sample molecules 
are ionised by reaction with gaseous reagent ions, formed 
from the reagent gas by a combination of electron impact 
ionisation and ion molecule collisions. Positively charged 
ions leave the ion chamber through the aperture in the ion 
exit (14). An electrical potential applied to the repeller 
(and thus to the complete ion chamber) via the needle 
assembly aids ion extraction. The CI ion chamber has no 
electron exit aperture because the electron beam is 
completely attenuated by the reagent gas. The trap current 
cannot therefore be used to control the lament current and 
so the latter is regulated to give a constant electron 
current to the ion chamber. 
1.3 Modifications to the HP5982A GCMS 
Two modifications had been made to the HP5982A GCMS by 
earlier users of the instrument: 
(a) The original dual packed columns, membrane separator, 
jet separator and heated blanket interface had been removed. 
These had been replaced with a capillary column and a 
commercially available heated interface (SGE pty, Victoria 
3134, Australia). The original packed column injector had 
been modified for use with the capillary column. 
(b) The CI reagent gas line had been connected to the 
unused mass spectrometer GC inlet. This allowed the reagent 
gas to be introduced into the source without it first 
passing through the GC column when CI spectra of probe 
samples were being recorded. 
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When this work began considerable difficulty was 
experienced with two needle valves in the SGE heated 
interface between the gas chromatograph and the mass 
spectrometer. These valves, one for isolating the mass 
spectrometer from the gas chromatograph and the other for 
controlling the gas flow passing through the interface, were 
found to leak. Further problems were encountered with 
cracks developing in the glass-lined metal tube (8) inside 
the source which delivers the GC column effluent to the EI 
and CI ion chambers (in the modified instrument one glass 
lined tube carries the CI reagent gas). These cracks 
exposed the column effluent to a bare metal surface, causing 
a dramatic loss in sensitivity when measuring trace amounts 
of analyte. In an attempt to solve these problems the 
capillary column was fed directly into the source (bypassing 
the two troublesome valves) and through the glass-lined tube 
to within 1 cm of the ion chamber. Unfortunately, the 
sharp bends in the glass-lined tube placed considerable 
strain on the column, causing it to break frequently. This 
also occurred when the glass-lined tube was replaced with an 
all-glass tube of the same dimensions but having bends of a 
slightly larger radius. The following modifications to the 
source were therefore made. A 6 mm diameter hole was cut in 
the side of the source mounting ring (20) and similar holes 
were cut in the source sealing shoe shim springs (21). The 
hole in the ion chamber body (5) and the hole in the source 
sealing shoe (22), both for receiving the original 
glass-lined tube carrying the column effluent, were 
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counter-bored to a diameter of 3.97 mrn. A short length of 4 
mrn Teflon tubing was passed down through the ion chamber 
body supporting cylinder (23) and through the new holes in 
the source mounting ring and in the shim springs. One end 
of the Teflon tubing was pushed tightly into the enlarged 
hole in the ion chamber body and the other end was pushed 
tightly into the enlarged hole in the source sealing shoe. 
The unused hole in the ion chamber body (which in the 
modified instrument was the entry port for the CI reagent 
gas) was blocked off with a short length of stainless steel 
rod. The ion source was then reassembled and returned to 
the instrument. The external inlet for the second column 
was capped, and the capillary column was fed into the 
remaining in , through the Teflon tubing, which acted as a 
guide, and directly into the ion source. A T-connector at 
the external inlet allowed the CI reagent gas to enter at 
this point and flow through the Teflon tubing (and around 
the column) and into the ion chamber: 
In any assay using QSIM it is important to ensure that 
the mass spectrometer is set to monitor the correct m/z 
values, and that there is no drift from these values once 
they are set. Each channel of the HP5982A's multiple ion 
detector (MID) supplies a tuning voltage of a to +10 volts 
to control the mass spectrometer over the mass range a to 
1000 atomic mass units. The four (or less) masses to be 
monitored are selected by adjusting four ten-turn 
potentiometers on the MID's front panel. The selected mass 
is displayed on a digital voltmeter (DVM). In this work, 
setting the required masses on the MID as originally 
supplied proved difficult. The large mass range covered by 
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each turn of the mass selection potentiometers meant that 
considerable care was required in adjusting these controls. 
Also, the last digit on the DVM displaying the selected 
masses was difficult to read and changed frequently, 
although numerous checks of the MID output voltages showed 
them to be stable. To solve these difficulties a new DVM 
was attached to the MID, and two resistors were inserted in 
the mass selection potentiometer circuit to reduce the mass 
range covered by the potentiometers. The details of this 
modification are described in Appendix A. 
An OCI-3 on-column injector (8GE Pty.) was fitted to 
the HP5982A's gas chromatograph and used for much of the 
work described in this thesis. The fitting the injector 
and its associated gas lines (including a flow controller) 
was straightforward and will not be described. 
2.1 Morphine 
CHAPTER 2 
INTRODUCTION 
Morphine, an alkaloid isolated from opium, is generally 
considered to be the most valuable of all pain relieving 
drugs. It is widely used to relieve moderate to severe pain 
associated with acute and chronic disorders, to provide 
analgesia during diagnostic and orthopaedic procedures and 
as a preoperative medication before surgery_ 
Morphine is variably absorbed from the gastrointestinal 
tract after oral ingestion and is thought to have a high 
first-pass hepatic extraction ratio (see note 1, Appendix B) 
so it is usually administered subcutaneously (S.C.), 
intramuscularly (I.M.) or intravenously (I.V.). After S.C. 
or I.M. injection absorption into the bloodstream is rapid 
and the drug is distributed throughout the body, but mainly 
in the kidneys, liver, lungs and spleen, with lower 
concentrations in the muscles .. The brain is the main s 
of action of morphine but relatively little of an 
administered dose penetrates the blood-brain barrier, the 
mechanism which prevents many substances in the blood from 
entering the central nervous systeml . 
The dosage of morphine that must be administered to a 
patient in pain to provide analges depends on the degree 
of analgesia required, the patient's response and the route 
by which the drug is given. Morphine given parenterally in 
a dose of 0.1-0.15 mg/kg body weight will achieve a plasma 
concentration of about 0.05 ug mL-l. This is the plasma 
concentration of morphine required to relieve moderate to 
severe pain and peak analgesia occurs within 20-90 minutes. 
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The excretion of morphine from the body is mainly via 
the urine, and is preceded by extensive metabolism to 
derivatives which are excreted more rapidly than the parent 
drug. The main metabolic pathway is conjugation with 
glucuronic acid to form morphine-3-glucuronide. Minor 
morphine metabolites which have been identified in human 
morphine addicts and/or non-addict patients are 
morphine-6-glucuronide in plasma and urine, and 
morphine-3,6-diglucuronide, morphine-3-ethereal sulphate, 
normorphine, normorphine-6-glucuronide and (tentatively) 
normorphine-3-glucuronide in urine. In healthy subjects 
(i.e. non-addict patients) with normal renal function 3-10% 
of an administered dose is excreted unchanged in the urine, 
about 70% as morphine-3-glucuronide and about 5% as 
normorphine. About 90% of total urinary excretion occurs 
within 24 hours. A small amount of a morphine dose is 
excreted unchanged into the faeces, largely in the bile2 . 
2.2 Morphine Disposition During Renal Failure 
Patients with renal failure often appear to be more 
sensitive to the effects of morphine than patients with 
normal renal function 3- 8 • Adverse drug reactions by renal 
failure patients to a therapeutic morphine dose include an 
unexpected degree of respiratory depression and a prolonged 
duration of drug action. The implication is that morphine 
distribution and elimination (disposition) is altered in 
some way by renal failure, in spite of the traditional 
belief that the liver is the main site of morphine 
metabolism9 . 
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Disturbances of drug-protein binding during renal 
failure have been suggested as a cause, at least in part, 
for increased sensitivity to morphine lO . Most drugs, 
including morphinell , normally bind reversibly to some 
extent to plasma proteins and changes to this binding', 
caused by altered concentrations or an altered binding 
capacity of proteins, can lead to unusually high or low 
plasma levels of unbound and active drug. Morphine binding 
in renal failure has been shown to depend on the 
concentration of total serum proteins and albumin lO and both 
of these concentrations are often diminished by renal 
failure lO . 
Morphine disposition during impaired renal function has 
been studied by comparing the pharmacokinetics of I.V. 
morphine in healthy volunteers and in patients with 
end-stage renal failure 12 . Plasma unchanged morphine was 
measured using high pressure liquid chromatography (HPLC). 
The rates of morphine elimination in the two groups were 
similar but morphine concentrations were higher in the 
patients than in the volunteers for the first 15 min after 
administration, implicating high early morphine 
concentrations in increased sensitivity to the drug. It was 
suggested that morphine-3-glucuronide, a major morphine 
metabolite9 ,13 that can produce analgesia and respiratory 
depression in dogs 14 but which is thought to be inactive in 
humans15 , probably accumulates in the plasma of anuric 
patients (those with no kidney function). 
The pharmacokinetics of morphine in patients undergoing 
renal transplantation and in control subjects have also been 
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compared16 . Using a "specific" radioimmunoassay (RIA) 
method17 to measure unchanged plasma morphine, the 
transplant patients were shown not to eliminate the drug 
from plasma until the transplant kidney began to function, 
at which point there was an abrupt change to the same 
elimination half-Ii as the controls. This suggested that 
patients with renal lure would accumulate morphine, 
rather than'eliminate the drug normally as had been 
previously reported. 
The group that demonstrated altered morphine 
pharmacokinetics in renal transplantation has recently 
reported unchanged morphine accumulation and reduced 
morphine clearance (volume of plasma cleared in unit time) 
in patients with renal failure 8 ,18. The clearance of 
morphine was related linearly to creatinine clearance18 . 
(Creatinine clearance is considered a good indicator of 
glomerular filtration rate and thus of renal function19 ). 
There has also been another report, by a fferent group, of 
morphine accumulation and reduced clearance during renal 
failure 20 . In all studies reporting sustained high plasma 
morphine concentrations the analytical method used to 
measure morphine was RIA. 
The finding that morphine elimination began only after 
the recovery of renal function during renal transplantation 
has been interpreted as demonstrating an important role for 
the kidney in unchanged morphine elimination, and led, in 
part, to the suggestion that the kidney, and not the liver, 
is the main site of morphine metabolism. This 
"renal hypothesis" or "renal glucuronidation theory", 
proposed by McQuay and Moore 6 , was supported by the reports 
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of unchanged morphine accumulation and reduced clearance 
during renal failure, and by other evidence that hepatic 
morphine metabolism may not be as important as is widely 
believed. Patients with severe hepatic cirrhosis have been 
found to tolerate morphine normally (although intolerance 
has also been reported 21 ) and to have morphine clearances 
similar to those in volunteers with normal liver function 22 . 
Drugs metabolised by the liver would be expected to have 
reduced clearance during cirrhosis and this has been found 
for pethidine and pentazocine 23 . Coadministration with 
morphine of drugs that lower liver blood flow would also be 
expected to reduce morphine clearance if morphine metabolism 
were primarily hepatic but two such drugs, cimetidine24 and 
propranolo1 25 , both appear to have no effect on clearance. 
Biochemical evidence suggests that a renal mechanism for 
morphine metabolism in humans may exist; rabbit kidney 
tubule is able to accumulate morphine and to metabolise the 
drug to its glucuronides 26 . 
All in all, there is considerable confusion regarding 
the disposition of morphine in renal failure and the role of 
the kidney in morphine metabolism. The studies suggesting 
that unchanged morphine elimination is impaired in renal 
failure, and which support the renal hypothesis, used an RIA 
method to determine plasma unchanged morphine 
concentrations. The validity of this assay has recently 
been questioned 27 ,28. An RIA using a similar antiserum 
(from the same animal) has been shown to overestimate 
unchanged morphine when morphine:morphine-3-g1ucuronide 
concentration ratios are greater than 1:10 27 . 
Morphine-3-g1ucuronide is present in chronically treated 
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patients at a concentration up to twenty-five times that of 
morphine 29 and this may have contributed significantly to 
the unchanged morphine concentration being measured. 
Another morphine metabolite, morphine-6-glucuronide 29 may 
also have cross-reacted with the morphine antisera28 . 
2.3 This Work 
Papaveretum (Omnopon@, Roche) is a standardised mixture of 
four opium alkaloid hydrochlorides. It contains the 
equivalent of anhydrous morphine 47.5 to 52.5%, anhydrous 
codeine 2.5 to 5%, noscapine 16 to 22%, and papaverine 2.5 
to 7%30. Papaveretum is widely considered superior to 
morphine in providing analgesia and sedation3l ,32, and is 
the most commonly used opoid in many New Zealand 
hospitals 33 . 
This section of the thesis describes a preliminary 
pharmacokinetic study of unchanged morphine in four patients 
with renal failure (one anephric) and three healthy 
volunteers after the intramuscular administration of 
papaveretum. The pharmacokinetics of morphine glucuronides 
in two of the patients were also studied. Unchanged 
morphine concentrations in serum samples were determined 
using GeMS with ammonia chemical ionisation mass 
spectrometry and quantitative selected ion monitoring. 
Morphine glucuronide concentrations were determined as the 
difference between morphine concentrations measured before 
and after liberation of the conjugates by enzyme hydrolysis. 
The study was prompted by the observation that papaveretum 
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occasionally has an excessive effect in renal failure 
patients33 and the disposition of morphine in such patients 
is still uncertain. 
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RESULTS AND DISCUSSION 
2.4 Analytical Methods 
2.4.1 Discussion of Preparative Procedures 
(a) N-Trideuteriomethylnormorphine 
N-Trideuteriomethylnormorphine ([2H3]-morphine, 
D3-morphine) was used as the internal standard for the 
quantitation of morphine in plasma and serum by GCMS. This 
compound is a stable isotope analogue of morphine and 
provides a number of advantages over other types of internal 
standard (see Section 1.1). 
D3-morphine was already available34 . To ensure the 
compound's purity it was recrystallised from methanol/water 
and then sublimed under vacuum. Mass spectral analysis 
showed the level of [lH3]-morphine (DO-morphine) contained 
in the purified D3-morphine to be less than 1%. 
(b) Morphine-(3B-D-glucopyranosyl)-uronate 
Morphine-(3S-D-glucopyranosyl)-uronate (morphine-3 
glucuronide) was prepared from morphine and methyl-
(tri-O-acetyl-a-D-glucopyranosyl bromide)-uronate using the 
method of Berrang35 (Figure 3). The crude product was 
purified by repeated recrystallisation from methanol. 
Methyl(tri-O-acetyl)-a-D-glucopyranosyl bromide)-uronate was 
formed by the acid catalysed acetylation of glucuronolactone 
to give methyl(tetra~O-acetyl-S-D-glucopyranuronate)36 which 
was then treated with hydrobromic acjd 36 . 
+ 
HO 
COOH 
OH 
N-CHa 
HO 
Figure.3. Formation of morphine - 3 - glucuronide 
HO 
HO 
TMSO 
BSA or 
BSTFA 
'"""-+__ N -CH3 
... 
TMSO 
Figure.4. Derivatisation reaction for morphine 
(TMS- i(CH3 )a) 
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2.4.2 Derivative Formation 
The gas chromatographic behaviour of morphine base is 
improved by derivatisation. This procedure increases the 
drug's volatility, and prevents its phenolic and hydroxyl 
groups interacting with the GC column to cause adsorption 
and tailing. Trimethylsilylmorphine derivatives were formed 
(Figure 4), prior to GCMS analysis, by reacting the dried 
residue of serum or plasma extracts containing morphine with 
N,O-bis-{trimethylsilyl)-acetamide (BSA) or 
N,O-bis{trimethylsilyl)-trifluoroacetamide (BSTFA) for 1 h 
at 600 C. GC analysis showed that derivatisation was 
completed in this time. 
2.4.3 Extraction Method for Morphine 
Morphine was extracted from plasma and serum by 
liquid-liquid extraction. The procedure was based on 
previously reported methods 37 ,38 and is fully described in 
the experimental section. All glassware was silanised to 
avoid loss of analyte and internal standard by adsorption 
onto glass surfaces. 
Plasma and serum were extracted as 1 mL aliquots in 10 
mL glass tubes with ground glass stoppers. The aliquots 
were spiked with internal standard, thoroughly mixed, and 
allowed to stand overnight to equilibrate (samples being 
analysed for total morphine were incubated with 
S-glucuronidase before extraction). Proteins were 
precipitated with acetone, and the acidified aqueous phase 
washed with benzene to remove acidic and neutral endogeneous 
material. (Washing the aqueous phase with toluene, a 
solvent which is less toxic than benzene, reduced the 
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recovery of morphine). The aqueous phase was then made 
alkaline, and morphine extracted with dichloroethane 
containing 30% (v/v) isopropyl alcohol. Morphine is an 
amphoteric drug and most efficiently extracted into an 
organic solvent from aqueous solution at a pH near its 
isoelectric point of S.9. This pH was attained using sodium 
hydroxide and a borate buffer. The dichloroethane-isopropyl 
alcohol was selected after evaluating six solvents or 
solvent mixtures by GC with flame ionisation detection, and 
ammonia CI GCMS for convenience, efficiency of morphine 
extraction, and ability to discriminate against unwanted 
endogeneous material (Table 1). After the extraction 
procedure was completed, the organic solvent was reduced in 
volume, transferred to a Reacti-vial and evaporated to 
dryness. The dried residue containing morphine was 
derivatised just prior to GCMS analysis. 
The recovery of morphine from plasma, using the 
extraction procedure finally ad~pted, was determined at 
morphine concentrations of 50 ng mL-l and 200 ng mL-l by 
ammonia CI GCMS and the results are shown in Table 2. 
No morphine was detected in plasma spiked with 
morphine-3-g1ucuronide at 200 ng mL-l. 
Solid phase extraction techniques offer a number of 
advantages over liquid-liquid extractions 39 ,40, and an 
attempt was made to extract morphine from plasma using 
Sep-pak CIS reverse phase cartridges (Waters Assoc.). 
Plasma spiked with morphine and morphine-3-g1ucoronide was 
aspirated through prewashed (methanol, water, buffer) 
cartridges and the morphine eluted with methanol. A good 
recovery of morphine was obtained but morphine-3-g1ucuronide 
Solvent 
n-butyl chlor 
Hexane 
Ethyl acetate 
Toluene-butanol 
Benzene 
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% morEhine Notes 
recovery 
from plasma* 
(n=5) 
'15-25% very clean extracts 
55-70% Problems with emulsions 
30-38% High level of co-extracted 
material 
60-70% Difficult to evaporate 
58-62% Toxic 
Table 1. Solvents evaluated for extraction of morphine 
1'P1asma morphine concentration 50 ng mL -1. 
Plasma morphine 
concn. 
50 ng mL-l 
200 ng mL-l 
% Recovery 
(mean of 5) 
76 
83 
Range 
73-81 
79-87 
Table 2. Recovery of morphine from plasma using 
dichloroethane containing 30% (v/v) isopropyl alcohol. 
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was also detected in the extracts. Elution of the conjugate 
could be prevented by washing the cartridge with water but 
this lowered the recovery of morphine to an unacceptable 
level. 
2.4.4 Hydrolysis of Conjugated Morphine 
Conjugated morphine in plasma and serum was hydrolysed 
using the enzyme S-glucuronidase (Sigma Type H-l from 
Helix pomatia). This enzyme also has some sulphatase 
activity. Plasma and serum samples were hydrolysed as 1 mL 
aliquots in the same glass tubes that were used for 
extracting unconjugated morphine. The samples were buffered 
to pH 5 and hydrolysed with the enzyme in a heated water 
bath at 370 for 24 h, in accordance with the enzyme 
manufacturer's instructions. The minimum quantity of 
S-glucuronidase (measured in Fishman Units) required to give 
the maximal yield of liberated drug was determined by the 
following procedure: Plasma containing 
morphine-3-glucuronide at a concentration of 5 ~g mL-l was 
prepared by adding a known mass of the conjugate to 
drug-free plasma. Aliquots of this plasma were spiked with 
D3-morphine and these samples were then hydrolysed with 50, 
100, 500, 1000, 2000, 3000, 4000 or 5000 Fishman Units of 
enzyme using the method which has just been described. 
After hydrolysis the samples were extracted and analysed 
using the method for unconjugated morphine. The yield of 
liberated drug, determined by measuring the ratio of DO- and 
D3-morphine, was found to increase and maximise at 2000 
Fishman units. The exact yield of liberated morphine was 
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not determined as no calibration graph was constructed, but 
this was estimated to be about 80% of available morphine. 
2.4.5 Mass Spectrometry of Derivatised Morphine 
The EI mass spectra, and methane, isobutane and ammonia 
CI mass spectra, for TMS2-DO-morphine and TMS2-D3-morphine 
were obtained and are shown in Figures 5 and 6. The EI 
spectra show molecular ion peaks (M+) (m/z 429 and 432), and 
extensive fragmentation with base peaks m/z 196 and 199 
respectively. The CI spectra show protonated molecular ion 
peaks (MH+) (m/z 430 and 433), and much less fragmentation. 
The base peak with ammonia reagent gas is MH+ but with 
methane and isobutane it is a fragment ion. Both compounds 
show less fragmentation with ammonia than with methane or 
isobutane. All the CI spectra show peaks corresponding to 
the electrophilic attachment of reagent gas ion, with a 
large fraction of the total ion current carried by MH+ -
methane (5%)~ isobutane (17%) and ammonia (3.2%). This 
suggested that monitoring MH+ under CI, particularly with 
ammonia reagent gas, might provide high sensitivity for the 
quantitation of morphine. Furthermore, the CI spectra all 
show sufficient fragmentation to allow high specificity to 
be attained by monitoring more than one ion. 
The sensitivities of an assay based on monitoring ions 
generated by either EI or CI, however, cannot be determined 
from normalised mass spectra41 ,42 since the ionisation cross 
section varies widely from EI to CI, and from one reagent 
gas to another. A comparison of sensitivities was made 
experimentally by injecting equal amounts of TMS2-morphine 
into the GCMS while the mass spectrometer was monitoring m/z 
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Figure 5. EI mass spectra of TMS2-DO- and TMS2-D3-morphine. 
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Figure 6. CI mass spectra of TMS2-DO- and TMS2-D3-morphine 
using CH41 C4HIO and NH3 as reagent gases. 
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429 using EI and then m/z 430 using CI for all three reagent 
gases. (The MS was retuned for maximum sensitivity in each 
case). Ion intensities were determined and compared by 
measuring peak heights on a chart recorder. The CI response for 
1·1H+ vii th ammonia was about twice that obtained with methane or 
isobutane, which in turn gave about the same response as the 
EI molecular ion. CI sensitivities were also compared for 
the base peak of TMS2-morphine with methane (m/z 414), 
isobutane (m/z 340) and ammonia (m/z 430), and again the 
response was greatest with ammonia. Based on these results, 
ammonia CI was selected for the quantitation of morphine in 
plasma and serum extracts. 
Ammonia CI was found to offer another advantage over 
EI, in addition to a lower detection limit. An ammonia 
plasma generally protonates only those compounds containing 
either a basic nitrogen or certain carbonyl functions 43 . At 
least four compounds with retention times close to that of 
morphine were detected in derivatised plasma and serum 
extracts when monitoring M+ at high gain by EI GCMS. Only 
one other compound was detected when monitoring MH+ in CI 
with ammonia reagent gas. 
2.4.6 Instrument Preparation 
A serious limitation to the sensitivity obtainable when 
determining trace levels of an organic compound by GeMS is 
imposed by adsorption or absorption of the analyte and the 
internal standard onto the mass spectrometer inlet system. 
There have been many reports of this problem,42,44 which is 
solved, in part, by saturating the inlet system with the 
compounds being determined. In this work the GC column and 
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the ion source were saturated with TMS2-DO-morphine and 
TMS2-D3-morphine before beginning analysis of the serum 
extracts, and following any dismantling, cleaning or change 
to the ion source or transfer line. Saturation was achieved 
by 20-30 injections of 100 ng of the two derivatives, and 
was followed by repeated injections of methanol until no 
mass spectrometer response was observed under conditions of 
high gain at m/z 430 and 433. 
The mass spectrometer's sensitivity was found to vary 
significantly from day to day. The instrument was therefore 
retuned on each occasion plasma or serum extracts were 
analysed. Reference compounds used for tuning were 
introduced into the ion source using a conventional 
direct-insertion probe. The mass spectrometer was tuned for 
ammonia CI operation by maximising the m/z 490 peak of 
chloropentaiodobenzene45 and using this peak and the 37C1 
isotope at m/z 492 for resolution adjustment. Final tuning 
was optimised using a 1:1 mixture of TMS2-DO-morphine and 
TMS2-D3-morphine. After adjusting the various ion-source 
and ion-focussing electrode potentials, the multiple ion 
detector (MID) control unit was used to set the mass 
spectrometer to monitor m/z 433, m/z 430 and m/z 340. The 
exact m/z monitored, which may be slightly different from 
these values because of mass defect and instrument 
calibration error, was set by scanning across each peak and 
setting MID mass scale control to give maximum ion 
current, as measured by pen deflection on the MID chart 
recorder. 
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2.4.7 Quantitative GCMS Analysis 
Quantitation of morphine was based on the MH+ ion 
intensities from TMS2-Do-morphine (m/z 430) and 
TMS2-D3-morphine (m/z 433). The resulting ion intensity 
ratio (intensity m/z 430/intensity m/z 433) was converted to 
a DO/D3 mass ratio using a calibration graph. Ion 
intensities were determined by measuring peak heights on a 
chart recorder. In order to reduce the measuring error the 
mass spectrometer sensitivity was adjusted to bring the 
peaks to as close as possible to full-scale deflection. 
Figure 7 shows the response at m/z 430 and 433 for an 
injection of a derivatised extract from plasma that 
contained DO- and D3-morphine, and for a derivatised extract 
from blank plasma. A set of initial calibration graphs was 
prepared to establish that the relationship between the mass 
spectrometer ratios and mass ratios was linear, and to 
define the errors in the analysis. The calibration graphs 
were constructed using extracted and derivatised plasma 
samples that contained DO- and D3-morphine in the ratios 
0.25, 0.50, 1.0 and 2.0 DO:D3. The preparation of the 
standard mixtures of DO- and D3-morphine used to spike the 
plasma samples is discussed in the experimental section. 
Two calibration graphs, one at a total DO + D3 concentration 
of 60 ng mL-l of plasma and the other at 400 ng mL-l, were 
obtained prior to beginning the pharmacokinetic study. 
These graphs are shown in Figures 8 and 9, and the ion 
intensity ratios and statistical analysis are given in 
Tables 3 and 4. A weighted linear least-squares 
procedure 46 (see Appendix C) was used to find the regression 
line for both calibration graphs. The absolute standard 
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m/z 433 
~/Z433 
m/z 430 
... ~~_m/z 430 
(a) (b) 
Figure 7. Response at m/z 430 and 433 near the retention time 
for TMS2-morphine for (a) an extract from blank plasma, and 
(b) an extract from plasma doped with DO + D3 = 60 ng mL-l morphine. 
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TABLE 3. CALIBRATION DATA AND REGRESSION ANALYSIS STATISTICS 
Concn. ln 
plasma 
(DO + D3) 
60 ng mL-l 
If 
II 
II 
Correlation 
coefficient (r) 
0.999 
DO/D3 ratio 
0.25 
0.50 
1. 00 
2.00 
Gradient 
1.00 
n 
5 
n 
II 
II 
% of explained 
variation 
100 r2 
99.9 
x s 
0.267 0.02907 
0.524 0.04904 
0.999 0.07738 
2.040 0.13148 
Parameters for Theoretical value 
least squares 
line 
y = a + bx 
y = 0.0167 + 1.00x 
of r at 99.9% 
0.6787 
w 
U1 
TABLE 4. 
Concn. in 
plasma 
(DO + D3) 
400 ng mL-l 
II 
" 
II 
Correlation 
coefficient 
0.998 
CALIBRATION DATA AND REGRESSION ANALYSIS STATISTICS 
DO/D3 ratio n x s 
0.25 3 0.263 0.00916 
0.50 " 0.485 0.2214 
1.00 II 0.976 0.04725 
2.00 It 2.09 0.05567 
Gradient % of explained Parameters for Theoretical value 
(r) variation least squares of r at 99.9% 
100 r2 line 
y = a + bx 
0.992 99.6 Y = 0.0101.+ 0.992'j.. 0.8233 
w 
~ 
37 
deviation in the measured intensity ratios was found to 
decrease as the DO/D3 ratio decreases, causing the smaller 
isotope ratios to be defined with greater precision. 
Weighting the regression line ensures that it is less 
sensitive to the large absolute errors at the upper extreme 
of the calibration and forces it to pass close to the more 
precisely defined points near the origin. The weighting 
factor used at each point was the inverse of the variance in 
the measured intensity ratios 41,42,46. 
The regression analyses were carried out by treating 
the mass ratios from the standard plasma samples as the 
independent variable and the measured ion intensity ratios 
as the dependent variable. This approach, which is 
sometimes used incorrectly41, assumes that the variance in 
mass ratios is less than the variance in the ion-intensity 
ratios 46 . It was adopted in this work because, although the 
60 ng mL-l and 400 ng mL-l calibration data were obtained 
from extracted plasma samples p~epared using two independent 
sets of standard DO- and D3-morphine mixtures, (one set for 
each level) a statistical analysis showed the two regression 
lines to be indistinguishable. 
Plasma samples containing DO- and D3- morphine in the 
ratio 4:1, were excluded as calibration standards. Two such 
samples were found consistently to give points below the 
least-squares line on the 60 ng mL-l calibration graph. 
This deviation was attributed to the (MH+3) peak (m/z 433) 
of TMS2-DO-morphine contributing significantly to the 
intensity of the MH+ ion of TMS2-D3-morphine (m/z 433) in a 
mixture with a large proportion of DO-morphine. Curvature 
in a calibration graph can also be caused by isotopic 
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impurity of the labelled compound. In the 1:4 DO:D3 case, 
TMS2-D3-morphine will show a low intensity ion at (MH-3) due 
to the presence of a small amount of unlabelled 
TMS2-DO-morphine. The degree of non-linearity introduced by 
this impurity was negligible, as shown by r values of better 
than 0.99 for both the 60 ng mL-l and 400 
ng mL-l calibration graphs. 
The accuracy of the procedure for determining morphine 
in plasma was assessed using a single doped plasma sample 
containing morphine at a concentration of 30 ng mL-l. Five 
1 mL aliquots of this plasma were doped with D3-morphine so 
that DO:D3 = 1, and another five 1 mL aliquots were doped 
with D3-morphine so that DO:D3 = 0.5. All ten samples were 
extracted and analysed using the procedures which have been 
described. Measured morphine concentrations were 
29.3 ± 1.4 ng mL-l when DO:D3=1 and 28.4 ± 1.7 ng mL-l when 
DO:D3=0.5. 
2.5 Patient Study 
2.5.1 Patients and Healthy Volunteers 
The four patients were men with renal failure, one (4, 
Table 5) being anephric (without kidneys). All four were on 
maintenance haemodialysis (see note 2, Appendix B). The 
important characteristics and laboratory data for each 
patient were supplied by medical staff at Christchurch 
Hospital and are given in Table 5. 
All patients had normal' serum concentrations of the 
enzyme aspartate aminotransferase (AST), indicating that 
they were free of liver disease. The concentration of this 
Table 5 Important characteristics and laboratory data for the renal failure patients. 
Patient Age Weight 
(years) (kg) 
1 60 80 
2 54 65 
3 41 60 
4 33 88 
a. Normal range 36-55 
Months on 
dialysis 
2 
1 
1 
114 
Cause of renal 
failure 
Polycystic 
kidney disease 
Membranous 
glomerulo-
nephritis 
unknown 
Goodpasture's 
syndrome or 
anti-glomerular 
basement membrane 
disease 
b. Serum aspartate aminotransferase; normal range <50 
c. Normal range 140-180 
Other medical Drugsd Albumina ASTb HaemoglobinC 
problems (gL-l ) IU/L (gL-l ) 
41 11 84 
Ischaemic Amphogel 
heart disease (aluminium 
hydroxide gel) 29 Chronic 14 50 
bronchitis 
Amphogel 45 14 75 
Anephric Alutab 
6 3x daily 
38 12 51 
d. All patients also receiving: Ferrous Gluconate 300 mg/day 
Calcitriol 0.25 ~g/day 
vitamin C 50 mg 3x week 
Vitamin B complex 3x week 
W 
1.0 
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enzyme is normally high in liver but low in blood. Damage 
to liver cells, caused by disease, liberates the enzyme 
causing a rise in the normal serum AST concentration. It 
was important to establish the absence of liver disease in 
the patients studied because of the major role the liver is 
believed to have in morphine metabolism. Serum albumin 
concentrations were in the normal range for all patients 
except one (2). Morphine in plasma, binds to this protein 
and the suggestion has been made lO that reduced albumin 
concentrations during renal failure may cause unusually high 
unbound plasma morphine concentrations. All patients had 
lower than normal haemoglobin concentrations. Anaemia 
frequently accompanies renal failure and is likely to cause 
increased cardiac output 47 . This increase in cardiac 
output, and hence in the circulation of the' blood, is a 
compensatory mechanism to maintain tissue oxygenation. The 
reduced haemoglobin concentrations observed suggested that 
the patients in this study had higher than normal blood 
flows. 
The volunteers were three male physicians, aged 34-41 
years. All were free of medical disease and were taking no 
regular medication. 
2.5.2 Clinical Protocol 
The study was approved by the Canterbury Hospital Board 
Ethical Committee, and all subjects gave written informed 
consent. All medical procedures were performed by medical 
staff at Christchurch Hospital. Papaveretum (0.25 mg/kg 
body weight) was injected into the deltoid muscle (a muscle 
in the upper arm). In the patients this was the fistula arm 
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(see note 3; Appendix B) Blood was obtained from a venous 
cannula (a tube inserted into a vein) in the contralateral 
arm immediately before injection and at intervals over the 
next 24 h. Samples were collected into plain tubes and the 
serum separated and stored at -20oC until assayed. 
The clinical response following papaveretum injection 
for both patients and healthy volunteers ranged from 
vomiting and somnolence to mild elation and hyperactivity. 
2.5.3 Analysis of Serum Samples 
Serum samples from the patients and healthy volunteers 
were analysed for morphine by ammonia CI GCMS, using the 
procedures which have been described. The intensities of 
MH+ ions from TMS2-DO-morphine (m/z 430) and 
TMS2-D3-morphine (m/z 433) were monitored for quantitation, 
and m/z 430 was monitored to rigorously establish morphine 
as the analyte. The samples were analysed in a random 
sequence and the time of sample. collection was unknown at 
the time of analysis. No morphine was detected in the serum 
samples taken immediately before papaveretum administration. 
The results for the analysis of the serum samples, and the 
calibration data and statistical analysis of these data, are 
shown in Tables 6-16. 
A calibration graph, at a total DO + D3-morphine 
concentration of 60 ng mL-l of plasma, was obtained and used 
on each occasion that unchanged morphine was measured. 
A similar, single, calibration graph, at a total DO + 
D3-morphine concentration of 400 ng mL-l of plasma was 
obtained for the determination of total (conjugated and 
unchanged) morphine in samples from two patients. 
TABLE 6 CALIBRATION DATA FOR MORPHINE STUDY 
-- ---------
Mass ratio Calibration lines 
(00/0 3) 1 2 3 4 5 6 
0.25 0.29 0.27 0.22 0.25 0.29 0.28 
0.26 0.22 0.29 0.30 0.28 0.28 
0.50 0.63 0.48 0.57 0.47 0.56 0.56 
0.53 0.57 0.45 0.56 0.55 0.61 
1. 00 0.92 0.93 1.12 0.93 0.98 0.99 
1. 04 1.12 1. 20 0.98 1. 07 1.06 
2.00 1. 87 2.15 2.21 1.87 2.01 2.14 
1. 97 2.08 2.14 2.19 1. 91 2.00 
1-7 DO + D3 = 60 ngmL-1 extracted from plasma 
B DO + 03 = 400 ngmL-1 " " " 
9 DO + 03 = 200 ngmL-1 II " II 
10 DO + 03 = 20 ngmL-1 " " .. 
7 8 
0.26 0.27 
0.29 0.25 
0.26 
0.49 0.51 
0.55 0.47 
0.48 
1.17 1.02 
0.92 0.96 
1.03 
2.18 1. 94 
2.13 2.01 
2.07 
9 
0.29 
0.27 
0.26 
0.53 
0.48 
0.51 
1. 03 
0.94 
0.97 
2.08 
1.93 
2.06 
10 
0.32 
0.19 
0.25 
0.49 
0.44 
0.60 
1.16 
0.89 
0.92 
1.87 
2.21 
2.32 
.",. 
IV 
TABLE 7 REGRESSION ANALYSIS STATISTICS FOR CALIBRATION DATA 
Calibration graph r Gradient 100r2 Least squares Line 
1 0.9916 0.9484 98.32 Y = 0.0523 + 0.9484x 
2 0.9939 1.0615 98.78 Y -0.0181 + 1.0615x 
3 0.9929 1.1277 98.58 Y = -0.0293 + 1.1277x 
4 0.9918 0.9727 98.37 Y = 0.0285 + 0.9727x 
5 0.9982 0.9697 99.64 Y = 0.0493 + 0.9697x 
6 0.9966 1.0199 99.32 Y = 0.0348 + 1.0199x 
7 0.9934 1. 0571 98.68 Y 0.0052 + 1.0571x 
8 0.9983 0.9894 99.64 Y = 0.0094 + 0.9894x 
9 0.9974 0.9781 99.48 Y = 0.0250 + 0.9781x 
10 0.9814 1.0489 96.31 Y = -0.0141 + 1.0489x 
Theoretical value of 
r at 99.9% 
0.9249 
" 
II 
.. 
II 
" 
" 
0.8233 
II 
" 
~ 
w 
TABLE 8 
Time after 
injection 
(min) 
15 
30 
45 
60 
75 
90 
105 
120 
150 
180 
210 
240 
RESULTS FOR UNCHANGED MORPHINE IN SERUM SAMPLES FROM HEALTHY VOLUNTEER 1 
D3-morphine Peak height Calibration Measured morphine 
conc. ngmL-l ratio graph conc. ngmL-l 
serum DO/D3 serum 
30.0 1.11 2 31. 9 
II 1. 83 
" 52.2 
II 1. 57 II 45.0 
" 1. 23 " 35.3 
" 
1.16 
" 33.3 
" 
1.11 
" 31. 9 
" 
1.09 
" 31. 3 
" 
1. 02 If 29.3 
II 0.98 II 28.2 
" 
0.78 II 22.6 
" 
0.63 
" 18.3 
" 
0.48 II 14.1 
~ 
~ 
TABLE 9 
Time after 
injection 
(min) 
15 
30 
45 
60 
75 
90 
105 
120 
150 
180 
210 
240 
RESULTS FOR UNCHANGED MORPHINE IN SERUM SAMPLES FROM HEALTHY VOLUNTEER 2 
D3-morphine Peak height Calibration Measured morphine 
conc. ngmL-l ratio graph conc. ngmL-l 
serum 00/0 3 serum 
30.0 0.93 1 27.8 
" 1.14 II 34.4 
II 0.99 II 29.7 
II 0.87 " 25.9 
/I 0.92 /I 27.4 
/I 0.93 " 27.8 
" 0.86 II 25.5 
" 0.81 " 24.0 
II 0.68 " 19.9 
.. 0.56 " 16.1 
.. 0.46 " 12.9 
.. 0.43 " 11.9 
~ 
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TABLE 10 RESULTS FOR UNCHANGED MORPHINE IN SERUM SAMPLES FROM HEALTHY VOLUNTEER 3 
Time after 
jection 
(min) 
2 
5 
10 
15 
20 
25 
30 
35 
40 
45 
55 
70 
80 
100 
130 
180 
240 
360 
480 
1440 
D3-morphine 
conc. ngmL-1 
serum 
30.0 
" 
" 
" 
" 
" 
" 
" 
" 
" 
" 
II 
" 
" 
" 
10.0 
" 
" 
" 
II 
n.d. none detected 
Peak height 
ratio 
DO/D3 
0.46 
1. 42 
1. 09 
1.15 
1. 41 
1. 06 
1.19 
1. 35 
1.11 
1.15 
1. 03 
0.94 
0.94 
0.73 
0.67 
1. 39 
0.85 
0.65 
0.25 
Calibration 
graph 
7 
" 
" 
" 
" 
" 
" 
n 
" 
" 
" 
" 
" 
11 
n 
10 
" 
II 
II 
" 
Measured morphine 
conc. ngmL-1 
serum 
12.9 
40.2 
30.8 
32.5 
39.9 
29.9 
33.7 
38.2 
31.4 
32.5 
29.1 
26.5 
26.5 
20.1 
18.9 
13.4 
8.2 
6.3 
2.5 
n.d. ~ 01 
TABLE 11 RESULTS FOR UNCHANGED MORPHINE IN SERUM SAMPLES FROM PATIENT 1 
Time after D3-morphine Peak height Calibration Measured morphine 
inj on conc. ngmL-l ratio graph conc. ngmL-l 
(min) serum DO/D3 serum 
15 100.0 0.54 9 53.0 
30 30.0 1.79 3 4B.4 
45 " 1.49 " 40.4 
60 II 1.27 " 34.6 
75 II 1.08 " 29. 5 
90 " 0.96 II 26. 3 
105 " 0.77 II 21. 3 
120 " 0.69 " 19. 1 
150 " 0.66 " IB.3 
180 " 0.50 " 14. 1 
215 10.0 1.20 10 11.6 
245 " 1. 02 II 9.9 
300 " 0.73 .. 7.1 
365 " 0.53 " 5.2 
420 II 0.52 11 5.1 
1430 " " n.d. 
n.d. none detected 
~ 
-...l 
TABLE 12 RESULTS FOR UNCHANGED MORPHINE IN SERUM SAMPLES FROM PATIENT 2 
Time after D3-morphine Peak height Calibration Measured morphine 
injection conc. ngmL-l ratio graph conc. ngmL-l 
(min) serum 00/0 3 serum 
19 30.0 1. 66 5 49.8 
30 .. 1. 0.4 " 30.6 
45 II 1.15 II 34.1 
60 II 1. 02 " 30.0 
75 II 0.611 II 19.5 
90 " 0.64 " 18.3 
105 II 0.62 II 17.7 
125 n 0.61 n 17.3 
150 II 0.55 .. 15.5 
180 10.0 J .02 10 9.9 
210 II 0.93 " 9.0 
240 " 0.50 " 7.8 
300 II 0.52 11 6.0 
360 " 0.55 II 5.4 
420 II 0.43 " 4.2 
480 II II n.d. 
1425 " II n.d. 
n.d. none detected 
,.!::l-
eo 
TABLE 13 RESULTS FOR UNCHANGED MORPHINE IN SERUM SAMPLES FROM PATIENT 3 
Time after D3-morphine Peak height Calibration Measured morphine 
injection conc. ngmL-l ratio graph conc. ngmL-l 
(min) serum DO/D3 serum 
5 30.0 1. 31 6 37.5 
10 " 1. 38 II 39.6 
15 " 1.23 " 35.2 
30 " 1. 61 " 46.3 
45 " 1. 4f) II 41. 9 
60 " 1. 05 " 29.9 
75 " 0.77 II 21. 6 
90 " 0.81 " 22.8 
105 " 0.74 II 20.7 
120 " 0.74 " 20.7 
150 " 0.57 II 15.7 
210 10.0 0.96 10 9.3 
240 " 0.84 .. 8.1 
300 II 0.56 " 5.5 
""" '-0 360 " 0.43 " 4.2 
TABLE 14 
Time after 
injection 
(min) 
15 
30 
45 
60 
75 
90 
120 
150 
180 
210 
240 
300 
RESULTS FOR UNCHANGED MORPHINE IN SERUM SAMPLES FROM PATIENT 4 
D3-morphine Peak height Calibration Measured morphine 
conc. ngmL-1 ratio graph conc. ngmL-l 
serum DO/D3 serum 
100.0 0.73 9 72.1 
" 0.65 II 63.9 
30.0 1.G3 4 55. 6 
" 1. 49 II 45. 1 
" 1. 44 II 43.5 
" 0.43 " 12. 4 
II 0.39 " 11.1 
10.0 0.74 10 7.2 
" 0.75 " 7.3 
" 0.52 " 5.1 
" 0.44 " 4.3 
" 0.25 " 2. 5 
V1 
o 
TABLE 15 RESULTS FOR CONJUGATED MORPHINE IN SERUM SAMPLES FROM PATIENT 1 
Time after D3-morphine Peak height Calibration Measured morphine Conjugated morphine 
injection conc. ngmL.,...l ratio graph conc. ngmL-1 conc. ngmL-1 
(min) serum DO/D3 serum serum 
15 200.0 0.37 8 72.9 19.9 
30 .. 0.73 " 145.7 97.3 
45 .. 0.87 " 174.0 133.6 
60 .. 1.08 " 216.4 181.8 
75 " 1.11 .. 222.5 193.0 
90 " 1.22 " 244.7 218.4 
105 " 1.21 " 221.4 242.7 
120 " 1.16 " 232.6 213.5 
150 " 1.37 " 275.0 256.7 
215 If 1.52 .. 305.34 293.8 
245 1.50 .. 301.3 291.4 
300 " 1.47 II 295.2 288.1 
365 1.45 " 291.2 286.0 
U1 
420 " 1.44 " f-' 289.1 284.0 
1430 If " 1.30 260.8 260.8 
TABLE 16 RESULTS FOR CONJUGATED MORPHINE IN SERUM SAMPLES FROM PATIENT 2 
Time after D3-morphine Peak height Calibration Measured morphine Conjugated morphine 
injection conc. ngmL-l ratio graph conc. ngmL-l conc. ngmL-l 
(min) serum 00/0 3 serum serum 
19 100 1.17 9 117.1 67.3 
30 If 1.41 .. 141.6 111.0 
60 .. 1.86 .. 187.6 157.6 
90 200.0 1.02 8 204.3 186.0 
105 II 1.17 .. 234.6 216.9 
125 .. 1.18 .. 236.6 219.3 
180 " 1.16 II 232.6 222.7 
240 to 1.31 " 262.9 255.1 
360 " 1.31 II 262.9 257.5 
420 " 1.24 " 244.6 248.8 
480 " to 1.31 262.9 262.9 
1425 It .. 1.04 208.3 208.3 
U1 
N 
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Samples found to have a DO + D3 ratio outside the 0.25 -
2.0 range covered by these calibration graphs were analysed 
again, after spiking with a more appropriate amount of 
internal standard, and using a DO- + D3-morphine = 20 ng 
mL-l or 200 ng mL-l calibration graph. Samples found to 
have a DO:D3 ratio near the extremes of the calibration 
graphs were also re-analysed if sufficient serum was 
available. 
A weighted linear least-squares procedure (Appendix C) 
was used to calculate the regression lines. The weighting 
factors used for the 60 ng mL-l calibration 
graphs were those calculated for similar graphs obtained 
earlier (Section 2.4.7). These weights were based on five, 
rather than two, replicate determinations at each mass 
ratio, and were thus more accurate. The weighting factors 
used for the 20, 200 and 400 ng mL-l graphs were ohtained from 
the actual calibration data. 
2.6 Pharmacokinetic Analysis 
2.6.1 Selection of a Model For Unchanged Morphine 
Various mathematical models can be used to simulate the 
processes of drug absorption, distribution and elimination 
in the body. These models provide equations to which 
experimental data can be fitted, allowing calculation of 
pharmacokinetic parameters. 
The simplest pharmacokinetic model is the 
"one-compartment-open model" in which the body is considered 
to be a single compartment. The model assumes that drug in 
the plasma reaches instantaneous equilibrium with drug in 
the tissues and that any changes occurring in the plasma 
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concentration reflect proportional changes in tissue drug 
levels. Drug elimination from the single compartment 
follows first order kinetics, giving a simple monophasic 
decline in drug concentration. 
Some drugs require a more sophisticated model to 
explain their plasma concentration-time curve. The 
"two-compartment-open model" assumes that a drug distributes 
into two compartments. The first or central compartment 
represents the blood, extracellular water and highly 
perfused tissues which the drug enters rapidly, and the 
second or peripheral compartment represents tissues that the 
drug enters more slowly. The two-compartment model predicts 
a biphasic decline in plasma concentrations during drug 
elimination. The initial and rapid a phase or distribution 
phase corresponds to drug in the first compartment entering 
the second compartment. After distribution, the decline in 
drug concentration enters the slower S phase or elimination 
phase, representing elimination.of drug from the central 
compartment. 
With both these models, and more complicated 
mUlticompartment models, drug can enter the system 
instantaneously (corresponding to a rapid intravenous 
injection), by a zero-order process (corresponding to an 
intravenous infusion) or by a first-order process 
(corresponding to absorption from the gastrointestinal tract 
or any other extravascular site). 
In this work serum unchanged morphine concentration 
data for each subject was analysed by computer using the 
non-linear least-squares regression analysis program 
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NONLIN 48. The data points were fitted, without weighting, 
to the following two functions. 
Cp 
Cp 
= 
= 
e-kat ) 
e-kat ) + Be-yt 
( 1 ) 
( 2 ) 
The quantity Cp represents the serum morphine 
concentration at time t, and A, B, ka, Sand yare 
coefficients which were varied iteratively by the program to 
give curves of best fit, determined by comparison of the sum 
of squares of the residual errors. These two functions 
represent one and two compartment open pharmacokinetic 
models respectively. The choice between equations (1) and 
(2) as functions of best fit to the experimental data for 
each subject was determined by a standard F-ratio test and 
the criterion that the model selected be the one with the 
fewest number of compartments which are necessary to 
adequately describe the experimental data. For all subjects 
there was no advantage gained by using equation (2) over the 
simple equation (1). 
2.6.2 Pharmacokinetic Parameters For Unchanged Morphine 
All pharmacokinetic parameters for unchanged morphine 
were calculated using conventional methods 49 • The 
coefficientkain equation (1) represents the first-order 
rate constant for absorption of morphine into the systemic 
circulation from the site of injection. These coefficients 
were used in equation (3) to calculate values for the 
absorption ha life (t~abs) 
t~ abs = ~n2 ( 3 ) 
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The coefficient S in equation (1) represents the 
first-order rate constant for morphine elimination. This 
elimination may be due to drug metabolism or excretion. The 
coefficients were used in equation (4) to calculate values 
for the elimination half-life (tk elim), which is the time 
2 
for the amount of morphine in the systemic circulation to 
fall to half of that initially present. 
t~ elim = ~n2 
S 
( 4 ) 
Two other pharmacokinetic parameters were calculated 
for each subject, the total body clearance (CL) and the 
apparent volume of distribution (V). Clearance, like 
t~ elim, characterises drug elimination, and is the volume 
of blood or plasma cleared of drug per unit time. For most 
drugs the clearance is constant over the plasma or blood 
concentration normally found: that is, elimination is not 
saturable, and the rate of elimination is directly 
proportional to concentration. Clearance values were 
calculated using equation (5). 
CL = F.D 
AUC 
( 5 ) 
The quantity F is the fraction of the administered morphine 
dose absorbed which reached the general circulation. The 
systemic availability of I.M. morphine has been shown to be 
100%50, and F was assumed to be 1. D is the dose of 
morphine administered. The usual form of morphine used in 
clinical practice is morphine sulphate, rather than 
anhydrous morphine as contained in papaveretum, so D was 
expressed as morphine sulphate equivalents. AUC is the area 
under the plasma morphine concentration versus time curve 
determined by the least-squares regression analysis. Values 
of AUC for each subject were calculated using equation (6), 
1 1 AUC = A (S - ka) 
where A, sand ka are as defined earlier. 
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( 6 ) 
The apparent volume of distribution is that volume of 
fluid into which a drug appears to distribute with a 
concentration equal to that in plasma. The volume, which 
does not necessarily correspond to a real anatomic volume 
(e.g. the blood volume), gives an indication of the extent 
to which the drug passes from the plasma into the tissues. 
Values of V for each subject were calculated using 
equation (7), 
V = CL 
S 
where cl and S are as previously defined. 
(7) 
Table 17 gives the dose of morphine administered 
(expressed as morphine sulphate equivalents), the 
coefficients to equation (1) calculated by NONLIN, and the 
derived pharmacokinetic parameters for each subject. Figure 
10 shows unchanged morphine concentration versus time 
curves, fitted by computer, for. the healthy volunteers and 
the renal failure patients. 
2.6.3 Statistical Analysis For Unchanged MorEhine 
Pharmacokinetic parameters for the healthy volunteer 
and renal failure groups were compared using unpaired 
Student's t-test (2-tailed). The mean half life of morphine 
absorption (t~ abs) and the mean half life of morphine 
elimination (tk elim) were significantly shorter in the 
2 
patients compared with the healthy volunteers (p < 0.05). 
The difference between the two groups in mean clearance (CL) 
and in mean volume of distribution (V) corrected for body 
weight did not reach statistical significance. 
Table 17 Pharmacokinetic parameters of papaveretum disposition after intramuscular administration. 
Healthy Dose A ka f3 t~ abs t~ elim AUC 
Volunteers (mg) (llg!L) (h) (h) (llgL-lh) 
1 13 .3 55.9 5.28 0.3255 .0.13 2.13 161.18 
2 15.3 39.24 6.29 0.2865 O.ll 2.42 130.74 
3 13.3 40.08 19.84 0.3515 0.03 1.97 112.02 
Mean 0.09 2.17 134.62 
± s.e.m. 0.03 0.13 14.32 
Renal 
Failure 
Patients 
1 13 .1 58.52 31.22 0.495 0.02 1.40 116.37 
2 11.3 48.58 22.77 0.526 0.03 1.32 90.16 
3 10.0 48.43 17.06 0 .. 455 0.04 1.52 103.71 
4 14.7 128.77 6.14 1.1015 O.ll 0.63 95.92 
Mean 0.05 1.21 101. 54 
± s.e.m. 0.02 0.20 5.67 
CL 
(Lh-l kg- 1 ) 
1.03 
1.30 
1.52 
1.28 
0.14 
1.22 
2.17 
1. 59 
1. 73 
1.67 
0.19 
V 
(Lkg-1 ) 
3.17 
4.54 
4.33 
4.01 
0.43 
2.92 
4.14 
3.51 
1. 57 
3.05 
0.55 
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Figure lOa. Measured serum morphine concentrations (0) and 
the computer-fitted curve (---) for healthy 
volunteers I and 2. 
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Figure lOb. Measured serum morphine concentrations (0) and 
the computer-fitted curve (---) for healthy 
volunteer 3 and patient 1. 
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Figure lOco Measured serum morphine concentrations (0) and 
the computer-fitted curve (---) for patients 2 
and 3. 
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Figure IOd. Measured serum morphine concentrations (0 ) and 
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Figure· II. Plasma morphine concentration versus time curves 
reproduced from the literature. 
2.6.4 Pharmacokinetic Interpretation 
(a) Unchanged Morphine 
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The literature contains several plasma unchanged 
morphine concentration versus time curves for healthy 
subjects who have been administered I.M. morphine 50 ,51. 
These are shown in Figure 11 as plots reproduced from the 
published curves using a grid to accurately read off the 
data points. Curves 1-3 are computer fitted curves that 
represent pharmacokinetic functions determined by non-linear 
least squares regression analysis which describe the plasma 
morphine concentrations at various times for three subjects 
who each received 10 mg of morphine sulphate. Morphine 
concentrations were measured by RIA. Curve 4 is a line 
which was drawn through mean measured plasma morphine 
concentrations for six subjects who each received 5.75 mg of 
N-methyl-14c morphine sulphate per square metre of body 
surface area. Morphine concentrations were determined by 
measuring the radioactivity of extracted plasma samples. 
Comparision of the pharmacokinetic curves calculated for 
unchanged morphine in the healthy volunteers in the present 
study with the literature curves shows that unchanged 
morphine concentrations for the healthy volunteers in this 
study were in the same range as those in the earlier 
reports. In this study morphine absorption into the 
systemic circulation from the site of injection was altered 
in the patients with renal failure. The shorter absorption 
half life shows that absorption was more rapid in the 
patients than in the healthy subjects. The most likely 
reason for the observed increase in the rate of morphine 
absorption in the patients is an increased blood flow at the 
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site of injection which would transfer drug into the 
systemic circulation more rapidly than normal. Cardiac 
output is likely to be greater in patients with renal 
failure 47 and there was reason to believe that the patients 
in this study had higher than normal blood flows (section 
2.5.1). Papaveretum was injected I.M. into the fistula arm 
of the patients, and blood flow is also likely to be greater 
in an arm with an arteriovenous fistula. 
The rate of morphine elimination was also altered in 
the patients with renal failure. The shorter elimination 
half life for the patients shows that this group eliminated 
morphine more rapidly than the healthy volunteers. Drug 
elimination half life is dependent on both the ability to 
eliminate drug (clearance) and the volume of distribution. 
This can be seen from rearrangement of equations 4 and 7: 
( 8 ) 
The mean volume of distribution was smaller and the mean 
clearance higher for the patients than for the healthy 
volunteers in this study. Unfortunately it was not possible 
to establish whether a change in the volume of distribution 
or a change in the clearance was responsible for the 
decrease in the elimination half life because the difference 
in the mean volume of distribution and in the mean clearance 
for the two groups did not reach statistical significance. 
Renal failure is known to cause a significant change in the 
volume of distribution for a number of drugs 52 • Changes in 
volumes of distribution are most often caused by unusually 
low binding of drugs to plasma proteins. The binding of 
many acidic drugs is decreased and the binding of many basic 
drugs is increased in renal failure. These changes in 
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binding are usually due to a combination of a decrease in 
serum albumin and a decrease in the binding capacity of the 
albumin due to a change in molecular configuration or an 
accumulation of an endogenous inhibitor. During renal 
failure there is excessive retention of protein metabolism 
by-products in the blood, a condition termed uremia. These 
endogenous substances, normally excreted in the urine, but 
retained in renal failure, can compete with drug at drug 
receptor sites on proteins and in tissues. A decrease in 
the protein binding of drugs which are normally highly 
protein bound makes more free (unbound) drug available for 
binding to the tissues and for possible clearance by the 
liver (but see below) thus decreasing the total (bound plus 
unbound) concentration of drug in the circulation and 
increasing the volume of distribution. Drugs which are not 
highly protein bound usually have little or no change in 
their volume of distribution. The protein binding of 
morphine in uremic patients has been shown to be impaired by 
lowered concentrations of plasma proteins and albuminlO . 
Because all patients except one in this study had serum 
albumin concentrations in the normal range (Table 5), and 
the extent of morphine's binding to plasma proteins is 
normally small (30%)10, changes in the protein binding of 
morphine in the patients studied are unlikely to have 
contributed to a change in the mean volume of distribution 
for this group. Impairment of drug binding at tissue sites 
would be expected to cause a decrease in the volume of 
distribution for drugs which are bound to a significant 
extent to tissues but which are not bound to a significant 
extent to plasma proteins. With one exceptionS3 , there is 
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little information on this point in the literature. 
Impairment of morphine binding at tissue sites due to 
retained endogenous substances, may have had some effect on 
the volume of distribution for the patients in this study, 
although this is unlikely because all patients were on 
maintenance haemodialysis. 
Clearance is a measure of the efficiency with which a 
drug is removed from the body. The sum of individual organ 
clearances equals the total drug clearance from the systemic 
circulation. Severe renal failure could be expected to 
reduce, or even prevent, drug clearance (by excretion and 
possibly metabolism) by the kidney, leaving the liver as 
(possibly) the main eliminating organ. Drugs which are 
efficiently eliminated from the blood by the liver (drugs 
with a high hepatic extraction ratio) have a clearance which 
depends on blood flow to the liver, and which is independent 
of any drug-protein binding. The clearance of drugs which 
are not efficiently extracted by the liver depends on the 
extent of drug-protein binding but is insensitive to changes 
in liver blood flow. That is, clearance depends on the 
liver's intrinsic clearance and not on the rate of drug 
presentation. Morphine has been reported to have a high 
hepatic extraction ratio (0.6-0.8) in healthy subjects 50 , so 
a change blood flow but not a change in the extent of its 
protein binding is likely to alter clearance by the 
liver via conjugation with glucuronic acid. The patients in 
this study probably had higher than normal blood flows, so 
that morphine clearance by the liver may have been 
increased. 
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(b) Conjugated Morphine 
Conjugated morphine concentrations were measured in 
the serum samples from patients 1 and 2. The conjugated 
morphine concentration versus time curves for these two 
patients are presented in Figure 12. The Figure also shows 
a mean plasma conjugated morphine concentration versus time 
curve reproduced from the literature5l for six healthy 
subjects who each received 5.75 mg of morphine sulphate per 
square metre of body surface area. The Figure shows that 
morphine glucuronides accumulated in the patients in the 
present study, and that high concentrations of metabolite(s) 
were present even after 24 hours following papaveretum 
administration. Morphine glucuronides in blood are excreted 
primarily by the kidney into the urine in heathly subjects. 
Some non-renal elimination also occurs via the faeces and 
via enterohepatic recirculation (see note 4, Appendix B). 
Renal failure would thus be expected to cause accumUlation 
of the conjugated metabolites, assuming the rate of 
conjugate formation is unaltered from normal. 
2.6.5 This Work and the Renal Hypothesis 
Morphine concentrations in the serum samples from the 
subjects who took part in this study were measured by a 
highly sensitive and specific analytical method, GCMS with 
QSIM. The results show that renal failure did not impair 
the elimination of morphine in the patients. The 
elimination half lives for morphine were not prolonged, and 
were actually slightly shorter than for the healthy 
subjects. It is worth noting that the anephric patient had 
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glucuronides (~ and.) concentrations for patients 1 and 
2, and of mean morphine glucuronides concentrations for 
six healthy subjects reproduced from the literature. 
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the shortest elimination half life. Morphine glucuronides, 
measured in two patients, were eliminated slowly. 
The renal hypothesis questions the traditional belief 
that the liver is the main site of morphine metabolism, and 
suggests that the kidney may have the major role. Morphine 
elimination and production of morphine metabolites should 
both be impaired in renal failure patients if the renal 
hypothesis is valid. The results from this work show that 
morphine elimination is not impaired by renal failure and 
strongly suggest that the renal hypothe s is not correct. 
The studies that have reported impaired morphine 
elimination in patients with renal insufficiency, and on 
which the renal hypothesis is largely based, have all used 
an RIA method to measure morphine concentrations. Results 
based on immunoassay determinations of morphine should be 
viewed with caution. The antisera used in immunoassays for 
morphine are unlikely to be completely specific for this 
drug and may cross-react to some extent with morphine 
metabolites. The antisera used by McQuay and Moore had a 
cross-reactivity with morphine-3-g1ucuronide of less than 
1%. The cross-reactivity with morphine-6-g1ucuronide was 
not investigated. Figure 12 suggests that shortly after 
morphine administration the concentration of conjugated 
morphine metabolites in serum from renal failure patients 
greatly exceeds the concentration of the parent drug, so 
that even a low level of cross-reactivity may lead to an 
overestimation of true morphine concentrations. 
Cross-reactivity by a morphine antiserum could be reduced, 
or even eliminated, by separating morphine from potentially 
interfering metabolites by extraction before the immunoassay 
determination is performed. The disadvantage of this 
procedure is that an unknown recovery of drug will be 
obtained. 
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Other evidence has been used to support the renal 
hypothesis. The oral bioavailability of a 
controlled-release morphine tablet has been measured and 
found to be 100%54. Oral bioavailability indicates the 
relative amount of an oral drug dose reaching the systemic 
circulation as unchanged drug, and depends on the dosage 
form of the drug (solubility, particle size etc.), and the 
drug's metabolism. After oral administration morphine (and 
other drugs) may be metabolised in the gut, the gut wall, 
the portal blood or the liver prior to entry into the 
systemic circulation. An oral bioavailability for morphine 
of less than 100% would be predicted if significant 
pre-systemic metabolism of morphine by the liver occurs. 
The study reporting an oral bioavailability of 100% for 
morphine used RIA to measure morphine concentrations, and 
cross-reactivity by the antiserum with conjugated morphine 
metabolites may have caused the estimate of bioavailability 
to be erroneously high. Other measurements of morphine oral 
bioavailability have produced figures in the range 
15-64%55 (morphine concentrations measured by gas 
chromatography). A significant difference exists between 
the relative potency of orally and parenterally administered 
morphine (30 mg orally is required for an analgesic action 
equivalent to that of 10 mg by injection). As has been 
noted in the literature, there is no simple explanation for 
this difference if the kidney is the major site of morphine 
metabolism. 
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The results of an investigation of morphine elimination 
in patients with liver disease have been interpreted as 
evidence that an important extrahepatic site for morphine 
metabolism may exist22 (although this site need not 
necessarily be the kidney). Patients with moderate to 
severe cirrhosis who were administered I.V. morphine were 
found to eliminate morphine and conjugated morphine 
normally. Plasma morphine concentrations, both before and 
after enzyme hydrolysis, were measured by gas 
chromatography, so lack of specificity for morphine, such as 
can occur with RIA, is less likely to have been a problem. 
A number of other drugs which are metabolised in the liver 
by conjugation with glucuronic acid, for example 
10razepam56 and oxazepam57 (drugs with low hepatic 
clearances), have also been found to have normal clearances 
in patients with liver disease. A possible explanation for 
these observations may be that the enzymes involved in 
glucuronidation are located deep within liver microsomes, 
making them less susceptible to liver damage. Another 
possible explanation may be that glucuronidating enzyme 
activity is not diminished by liver disease. Experiments 
with rats have shown that damaged liver tissue can have 
unaltered or even increased glucuronyl transferase 
activity 58,59. A difficulty with both of these explanations 
is that a frequent consequence of chronic liver disease is 
the development of intra- and extrahepatic vascular shunts 
that may carry drug in the portal circulation directly into 
the systemic circulation, reducing drug presentation to the 
liver's conjugating enzymes. There was evidence to suggest 
that such shunts existed in the patients in the morphine 
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metabolism-cirrhosis study, so the finding of normal 
morphine elimination makes it difficult not to postulate an 
extrahepatic site for morphine conjugation. 
The results from the present study do not explain the 
anecdotal observations made by many nephrologists of delayed 
recovery from the effects of morphine in patients with renal 
failure. Because morphine does not accumulate in these 
patients it is unlikely to be responsible for the prolonged 
duration of drug action. Morphine glucuronides do 
accumulate, but morphine-3-glucuronide is believed to be 
pharmacologically inactive in humans lS • 
Morphine-6-glucuronide may have considerable analgesic 
activity14,60,6l, and this metabolite may be present in the 
plasma of renal failure patients at concentrations exceeding 
those of morphine itself. In this study no attempt was made 
to distinguish between morphine-3-glucuronide and 
morphine-6-glucuronide when determining morphine metabolites 
conjugated with glucuronic acid. The glucuronide 
concentrations determined for two patients will almost 
certainly represent the total concentration of these two 
compounds. The presence of morphine-3-glucuronide did not 
affect determinations of morphine, and it is extremely 
unlikely that the presence of morphine-6-glucuronide would 
have any affect; morphine-6-glucuronide will be highly water 
soluble, and the results themselves suggest freedom from 
interference. 
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2.7 Conclusion 
This study has shown that morphine elimination is not 
impaired in patients with renal failure after the I.M. 
administration of papaveretum, and that morphine 
glucuronides are eliminated slowly in these patients. The 
resu s suggest that renal failure patients may eliminate 
morphine more rapidly than healthy subjects. This study has 
been unable to confirm the observation that patients with 
renal ilure have prolonged half lives for morphine 
elimination. Immunoassay determinations of morphine are 
unrel ble and probably overestimate morphine concentrations 
because the antisera cross-react with conjugated morphine 
metabolites. The renal hypothesis of morphine metabolism is 
probably not valid, and some other explanation is required 
to onalise the prolonged duration of morphine's action 
in patients with renal failure. The major site of morphine 
metabolism is also still uncertain. ~iore work is required 
to establish this site to enable rational dosing of patients 
with this valuable analgesic drug. 
3.1 Benztropine 
CHAPTER 3 
INTRODUCTION 
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Benztropine mesylate «3-diphenylmethoxy)-8-methyl-8-
azabicyclo[3.2.1]-octane methanesulfonate), is a synthetic 
tertiary amine antiparkinsonian drug. It resembles both 
atropine and diphenhydramine in chemical structure and 
exhibits anticholinergic, antihistaminic and local 
anaesthetic properties. Benztropine was first suggested as 
a therapeutic agent after the discovery that some 
antihistaminic drugs (e.g. promethazine and diphenhydramine) 
in addition to the belladonna alkaloids atropine and 
scopolamine, produce a beneficial effect in parkinsonism. 
New drugs, including benztropine, were synthesised in an 
attempt to combine both atropine-like and antihistamine 
activities in the same molecule .. The~e drugs generally 
contain structural features of atropine, and a 
diphenylmethane moiety or similar structural grouping which 
resembles that of the diphenhydramine group of 
antihistamines 62 ,63 (Figure 13). 
Benztropine is used to treat the symptoms of all forms 
of parkinsonism, including Parkinson's disease (paralysis 
agitans) and the parkinsonian-like effects induced by many 
antipsychotic drugs, especially phenothiazine derivatives. 
These drugs are used to treat severe psychotic illness and 
as a side-effect induce a parkinsonian-Ii syndrome which 
may be indistinguishable from paralysis agitans. 
Benztropine may be given alone or in conjunction with other 
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FIGURE 13. BENZTROPINE AND RELATED DRUGS 
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drugs, and may produce a number of adverse side-effects, for 
example dryness of mouth, blurred vision and urinary 
retention. 
Benztropine is dispensed under the proprietry names 
Benztropine, Benztropine mesylate, Congentin and Congenitol. 
It is available, by prescription, in tablets of 0.5, 1 and 
2 mg, and in a 1 mg mL-l solution for intramuscular or 
intravenous injection. The normal therapeutic daily dose is 
initially 0.5 to 1 mg and this is gradually increased up to 
2-6 mg 64 . 
There have been several reports describing the c nical 
s of therapeutic and excessive benztropine 
dosage 65 ,66 but very little information is available about 
concentrations in body fluids and organs. Plasma and urine 
concentrations of 79.5-125.6 ng mL-l and 5.3-123 
ng mL-l respectively have been measured in four psychiatric 
patients receiving antipsychotic medication and 2 mg 
benztropine twice daily67. There have been no reported 
pharmacokinetic studies for benztropine. 
3.2 Analytical Methods for Benztropine 
A spectrophotometric method for determining 
diphenhydramine and other compounds having a diphenylmethyl 
group, and thus applicable to benztropine, was 
described in 197568 . Acid hydrolysis of the ether linkage 
followed by oxidation gave benzophenone derivatives having a 
higher ultra-violet (UV) absorption coefficient than the 
original compounds, thus lowering the detection limit. The 
method was sufficiently sensitive to determine drug 
concentrations in urine after therapeutic dosages. 
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Gas chromatography using electron capture detection 
(e.c.d.) has been investigated as a method to assay diphenyl 
substituted compounds 69 . The electron capture sensitivity 
was enhanced by oxidising the compounds to benzophenone 
vatives prior to chromatography. The determination of 
benz tropine was not specifically considered but the method 
would appear sufficiently sensitive to detect the drug at 
nanogram concentrations. A problem with methods using 
oxidation is obtaining a high and reproducible yield of the 
benzophenone product, and a number of oxidising agents have 
been investigated70 ,71. 
Benztropine and two other anticholinergic agents have 
been included in an investigation of HPLC conditions 
suitable for the quantitative determination of common 
neuroleptic and antihistamine drugs in plasma72 - 74 . The 
anticholinergics are likely to be coprescribed with these 
drugs and may be present in the plasma samples being 
analysed. The conditions of the assay were optimised for 
measuring the neuroleptics and antihistamines by u.v., and 
later, electrochemical detection. Quantitation of the 
anticholinergics was not attempted but benztropine was 
reported to g only a small signal. 
The first and only assay specifically designed for 
determining benztropine was recently reported by Jindal et 
7 Using gas chromatography-mass spectrometry (GCMS), 
with the mass spectrometer operating under electron-impact 
conditions, benztropine concentrations in plasma and urine 
were found by measuring the rat of specific fragment ion 
intensities from benz tropine and a S.I.A. internal standard, 
trideuteriomethylnorbenztropine ([2H3]-benztropine). The 
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assay could measure 5 ng mL-I with about 6% precision and 
was used to measure drug concentrations in plasma and urine 
samples from patients on benztropine therapy. 
3.3 This Work 
A GCMS procedure with electron impact ionisation has 
been reported for determining benztropine in plasma and 
urine. This section the thesis describes a method for 
determining benztropine by GCMS with ammonia chemical 
ionisation mass spectrometry. [2H3]-benztropine was 
synthesised by a new method and used as an internal 
standard. The assay was developed for measuring benztropine 
concentrations in post-mortem blood and for detecting 
benztropine in post-mortem liver samples submitted for 
analysis to the Christchurch Laboratory of the Chemistry 
Division of the Department of Scienti c and Industrial 
Research (DSIR). This laboratory is responsible 
providing an analytical service for the Coroners in its 
area. The development of the assay was prompted by reports 
from the laboratory of difficulty in detecting benztropine 
using its normal drug screening procedures. 
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RESULTS AND DISCUSSION 
3.4 Discussion of Preparative Procedures 
(a) Benztropine 
Benztropine was prepared by the reaction of 
bromodiphenylmethane with tropine 75 , and the crude product 
purified by formation of its hydrobromide followed by 
recrystal s on from water. Bromodiphenylmethane 
was formed by reaction of benzhydrol with phosphorus 
tribromide 76 (Figure 14, scheme 1). 
(b) N-Trideuteriomethylnorbenztropine 
Jindal et a1 67 have previously prepared 
N-trideuteriomethylnorbenztropine by the reaction of 
norbenztropine with D3-methyliodide. Norbenztropine was 
formed by reaction of benztropine wi 
ethylchloroformate to form N-(2,2,2 
2,2,2-trichloro-
chloroethoxycarbonyl)-
norbenztropine which was then treated with zinc dust and 
acid (Figure 14, scheme 2). 
Attempts to duplicate this synthesis were unsuccessful. 
Formation of the carbamate proceeded smoothly, but all 
attempts to reintroduce the methyl group failed. An 
alternative route was therefore considered. Abdel-Monem and 
portoghese77 have previously shown that treatment of 
morphine with phenylchloroformate the carbamate which 
could then be reduced with lithium aluminium deuteride (LAD) 
to trideuteriomorphine. Based on s, N-(2,2,2-trichloro-
ethoxycarbonyl)-norbenztropine was treated with LAD under 
reflux in dry tetrahydrofuran and reaction fol by 
80 
Scheme 1: 
A + ... 
OH 
Scheme 2: 
Zn- AcOH 
Scheme 3: 
li 
Figure 14. Preparative methods for DO- and D3-benztropine 
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thin layer chromatography. When reaction was complete the 
mixture was quenched and workup gave N-trideuteriomethyl-
norbenztropine in 95% yield. The crude product was purified 
by formation of its hydrobromide which was purif by 
repeated recrystallisation from water. (Figure 14, scheme 3). 
Mass spectral analysis showed the level of Do-benztropine 
contained in purified D3-benztropine to be less than 
2.5%. 
3.5 Extraction Methods for Benztropine 
Benztropine has previously been extracted from plasma 
and urine at a pH of 9.2 using hexane 67 . The procedure 
included back extraction into a d, and gave an overall 
recovery of benztropine from doped samples of about 70%. 
The pH and solvent were probably se cted to give an 
acceptable recovery of the drug from the biological matrices 
and yet maintain the amount of co-extracted endogenous 
material at a reasonable 1. - In this work l-chlorobutane 
was selected as the solvent to extract benztropine from 
blood and liver samples. Aged blood is often haemolysed and 
cannot be separated from its cellular content and analysed 
as plasma. l-Chlorobutane has been widely used to extract a 
number of drugs from biological samples 78 - 83 , is noted for 
having efficient and clean extraction characteristics and is 
used by the local Government laboratory in its toxicological 
drug screening procedures. Hexane was rejected as an 
extraction solvent because it frequently gave emulsions and 
a lower drug recovery. 
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Post-mortem Blood 
Haemolysed blood was extracted as 1 mL aliquots in 
10 mL glass tubes with ground glass stoppers. The blood was 
made basic with sodium hydroxide and extracted twice with 
l-chlorobutane. The combined organic phase was reduced in 
volume and extracted into acid. After washing with the 
extraction solvent the aqueous phase was made alkaline and 
re-extracted with l-chlorobutane. Several drops of a 1% 
solution of hydrochloric acid in methanol were added and the 
organic solvent was evaporated. The extracts were 
reconstituted in ethanol and analysed by ammonia CI GCMS. 
The recovery of benztropine from blood using this 
extraction procedure, shown in Table 18, was determined 
using GCMS by spiking drug-free blood with benztropine at 
the concentrations shown, extracting the blood and adding 
D3-benztropine prior to evaporation of the organic solvent. 
Post-mortem Liver. 
Drugs in tissue samples must be released from their 
encapsulating environment prior to extraction. Methods used 
to destroy tissues rely upon the removal of proteins by 
protein hydrolysis or protein precipitation. Protein 
hydrolysis involves treating tissue homogenates with strong 
acid or alkali 84 , or with a proteolytic enzyme 85 • Protein 
precipitation involves the addition of a reagent, such as 
tungstic acid, to denature protein molecules 86 . In this 
work homogenised human post-mortem liver tissue was buffered 
at a suitable pH and incubated with the bacterial 
proteolytic enzyme subtilisin Carlsberge to hydrolyse tissue 
proteins. An aliquot of the liver digest was then extracted 
Blood benztropine 
concn. 
50 ng mL-l 
200 ng mL-l 
% Recovery 
(mean of 5) 
76 
78 
Range 
68-85 
73-82 
Table 18. Recovery of benztropine from post-mortem 
blood. 
Liver benztropine 
concn. 
250 ng g-l 
1 llg 
% Recovery 
(mean of 5) 
72 
74 
Range 
65-81 
66-88 
Table 19. Recovery of benztropine from post-mortem 
liver (drug added to liver digest) 
83 
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using the procedure described for blood and plasma, and 
analysed by GCMS. Subtilisin Car1sberge has been used 
previously to digest human liver tissues and 
1-ch1orobutane has been reported to give clean and 
emulsion-free extracts (determined using a 
nitrogen-phosphorus detector) of the resulting digest 87 . 
Enzyme hydrolysis avoids the disadvantages of drug 
degradation or drug coprecipitation common with the more 
traditional pre-extraction procedures used for drug analysis 
in tissues. Subtilisin Car1sberge cleaves most peptide 
bonds in proteins over a broad range of pH (7.0-11.0) and 
exhibits maximum proteolytic activity at lower temperatures 
than normally required for acid or alkaline hydrolysis. 
The recovery of benztropine from post-mortem liver, 
determined in a similar manner to blood, is shown in Table 
19. The recovery of benztropine extracted from both 
post-mortem blood and liver shows a variability that would 
be unacceptable in a quantitative assay using external 
standards. This variability presents no difficulties in the 
1 
assay described here, however, because an internal standard 
is used which accommodates this. 
3.6 Gas chromatography 
Benztropine is thermally stable and sufficiently 
volatile to be chromatographed without derivatisation. 
3.7 Mass Spectrometry of Benztropine 
The EI mass spectra, and methane, isobutane and ammonia 
CI mass spectra, for Do-benztropine and D3-benztropine were 
obtained and are shown in Figures 15 and 16. The EI spectra 
Figure 15. EI mass spectra of DO- and D3-benztropine. 
140 
100 -
-
-
-
-
..... 
CJ') 
t:: 
Q) 50 124 +' t:: 
...... 
-
..... 
201 
Q) 167 
c:: 
307 
- J - ,1.L 'I • • , 100 200 300 
m/z 
(a) EI mass spectrum of DO-benztropine 
100_ 143 
-
->, 
+' 
CJ') 127 165 t:: 
Q) 50. +' 
t:: 
...... 
0- 167 
& 
-
152 204 
-
310 
II II • 
• 
I I I 
100 200 300 
m/z 
(b) EI mass spectrum of D3":"benztropine 
85 
• I 
400 
4bo 
86 
Figure 16. CI mass spectra of DO- and D3-benztropine using 
CH4, C4H10 and NH3 as reagent gases. 
100 124 167 
>, 
.;..> 
Vl 
1= 
Q) 50 .;..> 
1= 
...... 30~ 
,...... 
Q) 
0:: 140 , 
~.~~~~~~~~Il+,I~·~~~~~~~~I~~~l~~~~~1 
100 200 300 400 
m/z 
(a) CI{CH4) mass spectrum of DO-benztropine 
100 - 127 167 
. 
>, 
.;..> 
'r- 143 Vl 
1= 
Q) 50 -.;..> 
1= 
..... 
. 
,...... 
Q) 
. 0:: 311 
195 
ILII ... 1 
~ 2[4 
j .. 
i l I 
100 200 
m/z 300 
400 
(b) CI(CH4) mass spectrum of D3-benztropine 
87 
100 167 
124 308 
140 
201 209 
40'0 
(c) CI(C4 0) mass spectrum of DO-benztropine 
167 
100-
-
-
>, 127 
-4-> 311 
U) 
-<:: 
Q) 50 -4-> 
<:: 
..... 
-
143 
.--
Q) 
c:: 
209 
-
- 2°l 
1 .. ~.. t I .L 
I I I 
100 200 
m/z 300 400 
(d) CI(C4HIO) mass spectrum of D3-benztropine 
88 
100 30 
>, 
+' 
til 
<= Q) 50 +' 
<= 167 ..... 
..... 
Q) 
IX 
2 a 
m/z 300 400 
(e) CI(NH3) mass spectrum of Do-benztropin~ 
311 
>, 
+' 
.~ 
til 
<= Q) 50; +' 
<= 
I'-< 
~ 167 
Q) 
IX 
100 200 300 400 
m/z 
(f) CI(NH3) mass spectrum of D3-benztropine 
89 
show molecular ion peaks (M+) (m/z 307 and 310), and 
extensive fragmentation with base peaks m/z 140 and 143 
respectively. The CI spectra show protonated molecu ion 
peaks (MH+) (m/z 308 and 311), and much less fragmentation. 
The base peak with ammonia reagent gas is MH+ but with 
methane and isobutane it is a fragment ion. Both compounds 
show less fragmentation with ammonia than with methane or 
isobutane. A large fraction of the total ion current is 
carried by MH+ - methane (7%); isobutane (12%) and ammonia 
(43%). This suggested that monitoring MH+ under CI, 
particularly with ammonia reagent gas, might provide high 
sensitivity for the quantitation of benztropine. As was the 
case with the CI spectra of TMS2-morphine, the CI spectra 
all show sufficient fragmentation to allow high specificity 
to be attained by monitoring more than one ion. 
A comparison of sensitivities was made experimentally 
by injecting equal amounts of benztropine into the GCMS 
whi the mass spectrometer was monitoring the base peak 
under EI (m/z 140) and then m/z 308 using CI for all three 
reagent gases. Ion intensities were determined and 
compared by measuring peak heights on a chart recorder. The 
CI response for MH+ with ammonia was about one and a half 
times that obtained with isobutane, which in turn was about 
the same as that obtained with methane. The CI response 
with all three reagent gases was greater than that obtained 
while monitoring the base peak under EI. CI sensitivities 
were also compared for the base peak of benz tropine with 
methane (m/z 167), isobutane (m/z 167) and ammonia (m/z 
308), and again the response was greatest with ammonia. 
Based on these results, ammonia CI was selected for the 
quantitation of benztropine in blood extracts and the 
detection of benztropine in liver extracts. 
3.8 GCMS Analysis 
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Quantitation of benztropine in blood was based on the 
MH+ ion intensities from Do-benztropine (m/z 308) and 
D3-benztropine (m/z 311). The procedures used were similar 
to those which have been described earlier for the 
quantitation of morphine in plasma. The GC column and the 
ion source were saturated with DO- and D3- benztropine 
before beginning analysis of the blood extracts. Figure 17 
shows selected-ion chromatograms (m/z 308 and 311) near the 
retention time for benztropine for extracts prepared from 
doped blood and for extracts prepared from blank blood. A 
calibration graph was prepared to establish that the 
relationship between the mass spectrometer ratios and the 
mass ratios was linear. The calibration graph was prepared 
using extracted blood that contained DO- and D3-benztropine 
in the ratios 0.25, 0.50, 1.0 and 2.0 DO:D3 with DO + D3 = 
100 ng mL-l. The preparation of the standard mixtures of 
DO- and D3-benztropine used to spike the blood is discussed 
in the experimental section. A weighted linear least 
squares procedure was used to find the regression line for 
the calibration graph, in a similar manner to that which has 
been described for morphine in the previous section of this 
thesis. The ion intensity ratios and statistical analysis 
are given in Table 20, and the calibration graph is 
presented in Figure 18. The data firm a simple linear 
relationship between the appropriate ion intensity ratios 
and the concentration of benztropine in blood. The accuracy 
m/z 311 
m/z 308 
m/z 308 
..... J~ 
(a) (b) 
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Figure 17. Response at m/z 308 and 311 near the retention time 
for benztropine for (a) an extract from blank blood and (b) an 
extract from blood doped with DO + D3 = 100 ng mL- l benztropine. 
TABLE 20. CALIBRATION DATA AND REGRESSION ANALYSIS STATISTICS 
Concn. in 
blood DO/D3 ratio n x s 
(DO + D3) 
100 ng mL-l 0.25 5 0.264 0.02904 
" 0.50 " 0.532 0.04628 
" 1. 00 " 1. 031 0.06283 
" 2.00 II 1. 943 0.17388 
Correlation Gradient % of explained Parameters for Theoretical value 
coefficient (r) variation least squares of r at 99.9% 
100 r2 line 
y = a + bx 
0.9992 0.9965 99.8 Y = 0.02088 + 0.9965x 0.6787 
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of the procedure for measuring benztropine was assess by 
six determinations of a single doped blood sample containing 
benztropine at a concentration of 50 ng mL-l. Measured 
levels were 47.4 ± 3.6 ng mL-l when DO:D3 = 1, and 46.2 
± 6.3 ng mL-l when DO:D3 = 0.5. 
Figure 19 shows selected-ion chromatograms (m/z 308 and 
311) near the retention time for benztropine for extracts 
prepared from doped and blank liver samples. The doped 
sample contained benztropine at a concentration of 50 ng 
gram- l of liver. The traces are free of interference at 
both m/z values, and suggest that D3-benztropine could also 
be used for the quantitation of benztropine in liver 
samples. 
3.9 Interference by other Drugs 
A list of drugs with which benztropine is commonly 
coadministered is presented in Table 2188. These drugs may 
be present in biological specime~s presented for analysis of 
their benztropine concentration. To determine if any of 
these drugs would interfere with the detection of 
benztropine in blood and liver samples analysed by the 
present method, a blood and a liver sample were spiked with 
each of the drugs listed in Table 21 at a concentration of 
10 ~g mL-l and 50 ~g gram- l respectively, and then extracted 
and analysed in the manner which has been described. No 
peaks were detected near the retention time of benz tropine 
while monitoring MH+ ions from DO- and D3- benztropine. 
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m/ z 311 
m/ z 311 
m/z 308 m/z 08 
(a) (b) 
Figure 19. Response at m/z 308 and 311 near the retention time 
for benztropine for (a) an extract from liver doped with DO + D3 
100 ng gram- l benztropine, and (b) an extract from blank liver. 
Triflupromazine 
Haloperidol 
Chlorpromazine 
Triazolam 
Lorazepam 
Lithium carbonate 
Table 21. Drugs commonly coadmini with benztropine 
3.10 Interpretation of Results 
The CI GCMS assay presented here is sens ive and 
specific for measuring benztropine concentrations in 
post-mortem blood, and for detecting benztropine in 
post-mortem liver. The assay is more spec and 
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potentially more sensitive than the GCMS assay using EI 
ionisation which has previously been reported67 • The 
absolute sensitivity obtainable depends on a number of 
factors including the volume (or mass) of sample which is 
prepared for analysis, and the amount of material which is 
injected onto the gas chromatographic column for detection 
by the mass spectrometer. In this work 1 mL blood samples 
and 10 gram liver samples were extracted, but this volume 
and mass could be increased to give a corresponding decrease 
in the assay's detection limit. The detection limit could 
be lowered still further by using an on-column injector on 
the gas chromatograph - the on-column injector used during 
the work described in Chapter 2 of this thesis was not 
available when the present assay was developed. In its 
present form a detection limit for benztropine of 2 ng 
mL-l in blood and 10 ng gram- l in liver seems possible. 
The extraction procedure described is adequate for 
handling partially decomposed blood and liver samples. A 
good recovery of benz tropine was obtained and the amount of 
coextracted endogeneous material was minimal, as indicated 
by a lack of any significant background ions when the total 
ion current for a blood and a liver sample containing no 
benz tropine was monitored. 
Other drugs commonly coadministered with benztropine 
were shown not to interfere with this assay. Blood and 
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ssue samples (liver in particular) are likely to contain 
metabolites of these drugs, however, and further work is 
required to determine if the chromatographic conditions used 
need to be modified to eliminate interference by these 
substances. 
lusion 
The procedure described here is highly specific and 
sensitive for detecting and measuring benztropine in 
post-mortem blood, and for detecting benztropine in I 
4.1 Datura Stramonium 
CHAPTER 4 
INTRODUCTION 
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Datura stramonium, also called Thorn Apple, Jimson weed 
and Jamestown weed, is a poisonous plant that grows in both 
waste and cultivated land in various parts of New Zealand. 
The plant is indigenous to the region of the Caspian Sea and 
is one of fifteen to twenty species of Datura which range 
from annual and perennial herbs to shrubs and trees. These 
plants are all members of the Nightshade (Solanaceae) 
family89,90. 
All parts of the D. stramonium plant (leaves, flowers, 
seeds and roots) contain the physiologically active tropane 
alkaloids (-)-hyoscyamine and (-)-scopolamine (hyoscine). 
The racemic form of (-)-hyoscyamine is atropine and this 
alkaloid may also be present in parts of the plant. 
Hyoscyamine and (-}-scopolamine are esters of tropic acid 
with the bases tropine and scopoline respectively. The 
structures of atropine and scopolamine have been presented 
in Figure 13. 
4.2 Poisoning by Datura Stramonium 
Atropine and scopolamine act on the body by preventing 
the neural transmitter acetylcholine from exerting its usual 
effect on receptor sites at nerve junctions. Symptoms of 
poisoning by these compounds are characterised by nausea and 
vomiting, a dry mouth, dilated pupils and hallucinations and 
fever. Accidental poisoning following ingestion of ~ 
stramonium is uncommon, both in humans and in livestock, in 
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this country and overseas. Accidental poisonings have 
mainly involved young children eating the plant seeds 9l - 95 , 
which have a high alkaloid content. In recent years there 
has been an increasing incidence of intoxication and 
poisoning following abuse of this plant. This is largely 
the result of the discovery that the leaves of D. stramonium 
can yield a legal and readily obtainable hallucinogen. 
Reported cases of abuse have usually involved the drinking 
of an aqueous plant extract, referred to as "Datura tea". 
The extent of the (often prolonged) effects of drinking such 
a preparation are illustrated by a recent newspaper report 
of three youths who were found experimenting with the 
plant 96 : 
"The teenagers were hallucinating some hours after they were 
brought into the (police) station and one of them, who had 
been released because he seemed better, was found upstairs 
at the station taking his socks off and saying he was going 
to bed. Another was convinced he was fixing the carburettor 
of his car. They were away with the fairies •.••• " 
4.3 This work 
There are numerous references in the literature 
concerning the alkaloid content of D. stramonium, but 
nothing is known about the alkaloid content of aqueous 
extracts prepared from the leaves. The chemical properties 
of atropine 97 , the main alkaloid in D. stramonium leaves, 
suggest that such extracts might contain high levels of this 
compound. 
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This section of the thesis describes a brief 
investigation to determine how efficiently atropine is 
extracted into water when leaves of D. stramonium are used 
to prepare a "Datura tea". The atropine concentration in an 
aqueous extract, and in an extract prepared by exhaustive 
organic solvent extraction of plant leaves was measured in a 
CI QSIM assay for atropine using trideuterionoratropine as 
an internal standard. The study was prompted by a request 
from a nearby Government Laboratory for information about 
atropine concentrations in aqueous D. stramonium extracts. 
The Laboratory has recently experienced difficulty in 
detecting atropine in post-mortem specimens taken from 
people who have died from a drug overdose and who may also 
have been drinking Datura tea at the time of the death. 
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RESULTS AND DISCUSSION 
4.4 Discussion of Preparative Procedures 
N-Trideute omethylnoratropine (D3-atropine) was prepared 
from N-trideuteriomethylnortropine and acetyltropylchloride 
using the method of Fung and DeGraw98 . Addition of formaldehyde 
to the Grignard derivative of phenylacetic acid, gave after 
hydrolysis, tropic acid 99 . This was treated with acetyl-
chloride and then thionyl chloride to give acetyltropyl-
chloridelOO (Figure 20, scheme 1). N-Trideuteriomethylnor-
tropine was prepared by the lithium aluminium deuteride 
reduction of N-ethoxycarbonylnortropine which was formed by , 
reaction of tropine with ethylchloroformate98 (Figure 20, 
scheme 2). Addition acetyltropylchloride to N-trideuterio-
methylnortropine with heating gave, after acid hydrolysis and 
workup, N-trideuteriomethylnoratropine which was purified by 
repeated recrystallisation from acetone (Figure 20, scheme 3). 
Mass spectral analysis showed the level of Do-atropine contained 
in the purified D3-atropine to be less than 1%. 
4.5 Plant Material 
Seeds of D. stramonium were obtained from the Botany 
Division of the Department of Scientific and Industrial 
Research. The seeds were sed in the Dniversity1s Botany 
Department glasshouse and several young plants were 
transferred to the University nursery. Leaves of the plants 
were collected when the plants were in the 
flowering-fruiting stage of development, this having been 
Scheme 1: 
(1) HCHD 
-----
(Z) H30 + 
Scheme 2: 
Q 
A a AHl II CH3CHZOCCl LiAlO4 OH a1 
Scheme 3: 
+ 
(1) 4hrs. at 90° A 
OH 
Figure 20. Preparative methods for D3-atropine 
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reported as the time of maximum alkaloid content. The 
leaves were air dried and stored in a tight containers. 
4.6 Preparation of an Aqueous Plant Extract 
Unsuccessful attempts were made to obtain information 
about how Datura tea is usually prepared. Several people 
who had been apprehended after drinking aqueous Datura 
extracts were approached (by the Police) but were unwilling, 
or unable, to give this information. 
One book, describing the history, cUltivation and use 
of garden herbs gives the following information concerning 
herb teas lOl : 
"They are made with an infusion fresh or dried leaves or 
flowers and boiling water, and Ie to steep for a few 
minutes with a lid on the pot or a cover over the cup, and 
drunk either hot or cold .... the amount to use when making a 
herb drink is a tablespoon of fresh l~aves to one pint of 
water, and half that amount of herbs, or even 
dried leaves. 1I 
S, if using 
Based on this recipe, dried D. stramonium leaves 
(2.50 g) were soaked in boiling water (1140 mL) in a covered 
glass beaker for several minutes. The aqueous extract was 
made up to a volume 2 L with water and four 1 mL aliquots 
of this extract were taken. To three of these samples was 
added an appropriate amount of D3-atropine. All samples 
were then made basic with concentrated ammonia solution and 
extracted with chloroform in 10 mL glass tubes with ground 
glass stoppers. The extracts were reconstituted in ethanol 
and kept cold until analysed. 
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4.7 Soxhlet Extraction of Plant Material 
The procedure for extracting alkaloids from the plant 
material was based on a previously reported methodl02 . 
Dried D. stramonium leaves (2.50 g) were exhaustively 
extracted in a soxhlet apparatus with a mixture of ammonia, 
ethanol and ether (total volume 1140 mL). The organic 
extract was made up to a volume of 2 L with additional ether 
and three 1 mL aliquots of the extract were taken. To each 
was added an appropriate amount of D3-atropine. The 
extracts were then taken up in acid, made basic with 
concentrated ammonia solution and finally extracted into 
chloroform as for the aqueous extracts. 
4.8 Gas Chromatography of Atropine and Scopolamine 
Both atropine and scopolamine can be chromatographed 
wihout derivatisation. A potential difficulty with the 
analysis of atropine and scopolamine by gas chromatography 
is the dehydration of these compounds in the heated injector 
port, and on the GC column, to form apoatropine and 
aposcopolamine respectivelyl03. This did not sent a 
problem for the quantitation of atropine in this work 
because D3-atropine was used as an internal standard. 
4.9 Mass Spectrometry of Atropine and Scopolamine 
The EI mass spectra of both atropine and scopolamine 
have previously been reportedl04 and will not be presented 
here. The ammonia CI mass spectrum of DO- and D3-atropine 
were recorded and are presented in Figure 21. The CI spectra 
show protonated molecular ion peaks (MH+) (m/z 290 and 293) 
and no significant fragment ions. 
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Figure 21. CI(NH3) mass spectra of DO- and D3-atropine. 
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(a) CI(NH3) mass spectrum of Do-atropine 
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(b) CI(NH3) mass spectrum of D3-atropine 
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4.10 Analysis of Plant Material 
A total ion current chromatogram of the aqueous plant 
extract to which no D3-atropine had been added was recorded 
with the mass spectrometer operating under EI conditions. 
Two peaks were seen which were identified from mass 
spectrum as atropine and scopolamine. The major component 
in the extract was atropine, as expected. The scopolamine 
concentration was estimated to be twenty to twenty-five 
times lower than the atropine concentration, based on 
measurement of peak heights. Quantitative analysis for 
atropine in both the aqueous and soxhlet extracts was 
performed using GCMS with the mass spectrometer operating 
under CI with ammonia reagent gas. Quantitation was based 
on measuring the MH+ ion intensities of DO- and D3-atropine. 
A calibration graph was constructed using standard solutions 
that contained DO- and D3-atropine in the ratios 0.25, 0.5, 
1.0, and 2.0 DO:D3 with DO + D3 = lOng ~L-l~ The 
preparation of these standard mixtures is discussed in the 
experimental section. A weighted linear least squares 
procedure was used to find the regression line for the 
calibration graph, in a similar manner to that which has 
been described for morphine and benztropine in earlier 
sections of s thesis. The measured ion intensity ratios 
for the calibration standards and associated statistical 
analysis, and the resulting calibration graph are presented 
in Table 22 and Figure 22 respectively. The measured ion 
intensity ratios for the aqueous and soxhlet plant extracts, 
and the associated calculations to determine the atropine 
concentrations in these extracts are presented in Table 23. 
TABLE 22. CALIBRATION DATA AND REGRESSION ANALYSIS STATISTICS 
Concn. of 
injection 
(DO + D3) 
10 ng j.1L-l 
II 
II 
II 
Correlation 
coefficient (r) 
0.9999 
DO/D3 ratio 
0.25 
0.50 
1. 00 
2.00 
Gradient 
1. 0199 
% of explained 
variation 
99.8 
n x s 
3 0.257 0.01527 
" 0.523 0.06028 
It 1.034 0.04163 
" 2.023 0.08145 
Parameters for Theoretical value 
least squares of r at 99.9% 
line 
y = 0.0034 + 1.0199x 0.8233 
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Figure 22. Calibration graph for atropine determination 
• = mean of 3 measurements) 
TABLE 23. RESULTS FOR ATROPINE CONCENTRATIONS IN PLANT EXTRACTS 
AQUEOUS EXTRACT 
Sample No. 
1 
2 
3 
SOXHLET EXTRACT 
1 
2 
3 
D3-atropine concn. 
ng ].lL-l extract 
5.0 
" 
II 
5.0 
" 
II 
Peak height ratio 
0.59 
0.62 
0.61 
0.66 
0.63 
0.65 
Measured atropine concn. 
ng ].lL-l extract 
2.88 
3.02 
2.97 
mean (±SD) = 2.96 (± o.on 
3.22 
3.07 
3.17 
mean (±SD) = 3.15 (± 0.08) 
I-' 
0 
!,.Q 
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4.11 Interpretation of Results 
Atropine in the extract obtained by exhaustive solvent 
extraction of D. stramonium leaves can be assumed to 
sent the total {-)-hyoscyamine and atropine in the 
plant material {extraction of the plant material will result 
in racemisation of (-)-hyoscyamine to atropine). The 
atropine concentration measured in the soxhlet extract 
corresponds to a combined (-)-hyoscyamine and atropine level 
in the plant leaves of 0.25% by dry weight. This level is 
in good agreement with alkaloid levels reported in the 
literature for dried D. stramonium leaves l05 . The atropine 
concentration measured for the aqueous D. stramonium extract 
corresponds to a 94% recovery of available (-)-hyoscyamine 
and atropine. Hyoscyamine and atropine were thus very 
efficiently extracted from D. stramonium leaves simply by 
soaking the leaves in boiling water for several minutes. 
A summary of the s of atropine in relation to 
dosage, reproduced from the literaturel06 , is presented in 
Table 24. Wide variation in tolerance to atropine is known 
to st, and what constitutes a fatal dose is unclear. 
Although 10 mg of atropine produces severe distress, many 
adults have recovered from a single dose of 100 mg and more. 
Recovery after ingestion of 1000 mg has been reportedl07 . 
It is thus very difficult to make a concise statement about 
the .dangers associated with drinking an aqueous extract 
prepared from D. stramonium leaves. The amount of atropine 
ingested will depend on the time of year that the plant 
material is collected, the amount of plant material and the 
volume of water used to prepare the extract, and the volume 
of extract which is consumed. From the results of this 
Table 24. 
DOSE 
0.5 mg 
1.0 mg 
2.0 mg 
5.0 mg 
10.0 mg 
and 
more 
EFFECTS OF ATROPINE IN RELATION 
TO DOSAGE (Reproduced from Ref. 106) 
EFFECTS 
Slight cardiac slowing: some dryness of 
mouth: inhibition of sweating 
Definite dryness of mouth; thirst; accel-
eration of heart, sometimes preceded 
by slowing; mild dilation of pupil 
Rapid heart rate; palpitation; marked 
dryness of mouth; dilated pupils; some 
blurring of near vision 
All the above symptoms marked; speech 
disturbed; difficulty in swallowing; 
restlessness and fatigue; headache; 
III 
dry, hot skin; difficulty in micturition; 
reduced intestinal peristalsis 
Above symptoms more marked; pulse rapid 
and weak; iris practically obliterated; 
vision very blurred; skin flushed, hot, 
dry, and scarlet; ataxia, restlessness 
and excitement; hallucinations and 
delirium; coma 
112 
study it could reasonably be expected that several 
medium-sized glassfuls of an aqueous extract prepared from 
D. stramonium leaves in the manner described in this thesis 
would contain sufficient atropine to constitute a dangerous 
drug dose. 
4.12 Ius ion 
An aqueous extract of D. stramonium leaves will contain 
most of the atropine present in the plant material. 
Drinking such an extract is likely to be highly dangerous. 
CHAPTER 5 
INTRODUCTION 
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5.1 Mass Spectrometry of Involatile and Thermally Labile 
Compounds 
A major limitation in the application of the more 
common mass spectrometric techniques of electron impact 
(EI), field ionisation (FI) and chemical ionisation (CI) to 
the identification and structural determination of thermally 
unstable or involatile compounds is that the sample must be 
vaporised before ionisationl08 ,109. Such compounds often 
decompose or fail to vaporise in the mass spectrometer ion 
source, and the resulting spectra give very little useful 
information. Chemical derivatisation of polar functional 
groups, which reduces intermolecular hydrogen bonding, has 
been widely used to increase the volatility and thermal 
stability of "difficult" samples llO . Unfortunately 
derivatisation adds an extra step to sample analysis, and 
also gives an increase in molecular weight which is 
proportional to the number of polar groups present. 
In recent years a number of techniques have been 
developed which allow many non-derivatised thermally 
unstable and involatile compounds to be investigated almost 
routinely by mass spectrometrylll-115. These techniques 
have used a wide variety of methods to ionise sample 
molecules, ranging from simple heating of a metal substrate 
in the presence or absence of a strong electric field to 
impact with very high energy particles. Three of these 
techniques which are now commercially available are 
described below. 
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(a) Field desorption (FD)lll 
b A very strong electrostatic field (1-4 ViA) is used to 
ionise sample molecules absorbed on a specially prepared 
surface, and a combination of this field and thermal energy 
desorbs the ionised sample molecules. This technique was 
introduced by Beckey in 1969 and is probably still the most 
widely used method for the analysis of non-volatile samples. 
(b) Plasma desorptionl12 
Simultaneous ionisation and desorption of sample 
molecules is achieved by impact of high energy (100 MeV) 
fission products from 252Cf onto the back side of metal foil 
coated with a molecular layer of the sample. This technique 
often gives molecular weight information when FD does not. 
(c) Fast Atom Bombardment (FAB)115 
A beam of rare gas atoms bombards the sample suspended 
in a relatively involatile liquid carising desorption of 
ions. This technique is perhaps the most important recent 
development in mass spectrometry and it can provide 
molecular weight information for very high molecular weight 
compounds in addition to those which are involatile and 
thermally fragile. 
5.2 Desorption Electron Ionisation and Desorption Chemical 
Ionisation 
Another approach to obtaining useful mass spectral 
information for involatile and thermally unstable compounds 
has been to minimise the distance within the mass 
spectrometer source between the site of sample 
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volatilisation and the site of ionisation. This strategy 
has led to the development of the so called "in-beam" 
techniques of desorption electron ionisation 
(DEI)116-124 and desorption chemical ionisation 
(DCI)125,126 mass spectrometry. In DEI and DCI the sample 
to be analysed is deposited on a surface and introduced 
directly inside the mass spectrometer ion source by means of 
an extended direct insertion probe. This replaces the usual 
practice of vaporising the sample outside of the source, 
which generally results in pyrolysis of thermally labile 
compounds. The sample or the ion source is then heated 
(after the reagent gas has been introduced for DCI). Under 
these conditions many involatile and thermally unstable 
compounds give mass spectra which exhibit abundant 
protonated molecular ion and fragment ion peaks which would 
not be observed using a conventional solids probe. For DCI 
spectra the extent of sample fragmentation is generally 
greater than that observed under FD MS so the spectra give 
more structural information about the samp 
The main advantage of DEI and DCI MS is its simplicity. 
Any mass spectrometer can be equipped with a direct exposure 
probe without major modification, and at relatively low 
cost. By comparison, FD, plasma desorption and FAB methods 
are expensive and are usually only available on larger 
magnetic sector instruments. 
Two approaches have been taken in an effort to enhance 
the volatility of thermally labile molecules deposited on 
the tip of an extended probe - the use of inert surface$ and 
rapid probe heating. Dispersal of molecu onto a 
relatively inert surface reduces the binding energy of the 
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sample to the surface and makes the desorption process more 
competitive with decomposition. Materials used as 
vaporisation surfaces have included glass 125 ,127, 
quartz l17 ,128-l30, Teflonl19 ,131,132, VespeI133 ,134, bare 
and polyimide coated wires124 ,135-l38, and polyimide-coated 
fused silica capillary tUbing139 . The rapid heating 
technique is based on a kinetic analysis of the competitive 
decomposition and evaporation processes. It has been 
shownl19 ,120 that rapid heating of the probe tip favours the 
desorption of intact neutral molecules over decomposition. 
For this reason heating rates of lOoC per second (termed 
"flash desorption") have been used. A consequence of rapid 
sample heating is that desorption occurs very quickly so 
scanning of the mass spectrum must be very rapid. Computer 
data acquisition is usually necessary (alternatively, 
simultaneous detection of all ions formed using a 
photographic plate is possible with a mass spectrometer of 
Mattauch-Herzog geometry124). 
The mechanism of the ionisation process occurring at 
the tip of the extended probe during DEI and DCI is still 
uncertain. Rapid heating of the sample on an inert sur ce 
presupposes the process to involve desorption of neutral 
sample molecules from the surface followed by their 
gas-phase ionisation by the electron beam (in DEI) or by the 
reagent gas plasma (DCI)134. Direct ionisation of the 
sample on the probe surface followed by desorption of ions 
(i.e. a heterogeneous reaction), has also been suggested as 
a mechanism132 , and experimental support for both hypotheses 
has been presented. A review of the evidencel40 has 
concluded that in most reported DEI and DCI experiments the 
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process has been one of short path thermal volatilisation 
followed by gas phase ionisation. 
Spectra from DEI and DCI experiments showing molecular 
ions usually appear immediately after insertion of the 
extended probe, and the spectra invariably exhibit 
protonated molecular ions (MH+). Later spectra under DEI 
begin to look like conventional EI spectra. The formation 
of MH+ ions during DEI has been attributed to the rapid rise 
in the ion source pressure as molecules are desorbed from 
the probe surface, temporarily causing chemical ionisation 
conditions. Most experiments have been conducted 
essentially without regard to quantitative sample 
measurements, and most spectra have been obtained from 
sample sizes of 100 ng to a few micrograms. It appears that 
the sensitivity of DCI is comparable to that of ordinary CI. 
To date, most DEI- and DCI-MS studies have been 
concerned with developing the in-beam technique, and 
demonstrating its ability to provide molecular weight and 
structural information for involatile and thermally unstable 
compounds. Some classes of compound for which in-beam 
spectra have been reported are listed in Table 25. The 
following examples, taken from this list, illustrate the 
potential of DEI- and DCI-MS. 
Amino acids: 
Most amino acids show molecular ion peaks in their EI, 
CI and FI mass spectral09 ,145-148. Creatine and arginine 
are exceptions, probably because both compounds undergo 
thermal dehydration to form the corresponding cyclic 
lactones at temperatures below that required for 
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volatilisation146 ,148. The DCI mass spectra obtained with 
methane126 , isopentane132 and isobutane133 as reagent gas 
show prominent MH+ ion peaks for both the parent compounds 
and the dehydration products. 
Carbohydrates: 
The ability to analyse carbohydrates by mass 
spectrometry is severely limited by the thermal instability 
and extremely low volatility of these compounds124 • DEI 
mass spectra which show prominent MH+ ions for sucrose and 
lactose have been reported124 . 
Polypeptides: 
The low volatility of these compounds, and the small 
number of fragment ion peaks in their FD spectra149 , limit 
the utility of EI-, CI- and FD-MS for determining the 
sequence of amino acids present. Derivatisation can be used 
to increase the volatility but this can consume considerable 
amounts of sample150 • DCI-MS spectra for a number of tri-, 
tetra-, and pentapeptides have been recorded which exhibit 
MH+ ion peaks and fragmentation sufficient to derive a 
unique amino acid sequence120 ,125,126. 
5.3 This Work 
The laboratory in which the work described in this 
thesis was undertaken operates an A.E.I. MS902 high 
resolution magnetic sector mass spectrometer and a Hewlett 
Packard 5982A GCMS. The MS902 is an EI-only instrument, and 
the HP5982 prov~des EI and CI. Both instruments are used 
for research projects in toxicology, pharmacology and 
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environmental analysis and to provide routine mass spectral 
information for a number of research groups in other fields, 
both within and external to the University. Neither 
instrument has been able to provide satisfactory mass 
spectra for the increasing number of unstable or high 
molecular weight compounds being submitted, particularly 
those from the large marine chemistry group. This section 
of the thesis describes modifications made to the Hewlett 
Packard instrument to allow it to be used in DEI or DCI mode 
with a commercially available DCI probe. The effectiveness 
of these modifications is discussed. 
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Table 25 Classes of compound previously studied by DEl-
and/or DCI-MS. 
1. Glucuronides 141,142,138,139 
2. Carbohydrates 124,138,139 
3. Steroids 143,142,138 
4. Prostaglandins 142,138,139 
5. Nucleotides 126 
6. Amino acids 126,132,133 
7. Nucleic acids 137 
8. Antibiotics 144 
9. polypeptides 125,120,126,139 
10. Salts of organic acids 126 
11. Nucleos s 126,142 
12. Pesticides 126 
13. Glycosides 135,142,138 
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RESULTS AND DISCUSSION 
5.4 Probe Installation 
5.4.1 General Considerations 
In providing the HP5982A with DEI and DCI capability 
two minimum goals were set: 
1. Existing parts of the instrument which required 
modification but which could not readily be replaced should 
be refabricated to incorporate the necessary changes. In 
this way the instrument could always be restored to its 
original state. 
2. The existing EI and CI sensitivities of the 
instrument should not be significantly degraded at the 
expense of obtaining DEI and DCI capability. 
5.4.2 DCI Probe 
The DCI probe was supplied by Vacumetrics (Vacumetrics, 
Ventura, Ca.) and is a modification of that described by 
Bruins135 • A scale drawing of the probe is presented in 
Figure 37. All major parts of the probe are constructed 
from stainless steel. The filament is a loop of platinum 
wire mounted on two pins held in position by a ceramic 
spacer. The filament assembly (1) is mounted on the inner 
shaft (2) which can be slid along its axis within the outer 
shaft (3) by moving the probe handle (4). This movement 
permits the filament tip to be extended inside the ion 
chamber after the probe has been inserted through the solids 
probe insertion lock of the mass spectrometer. The maximum 
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possible extension of the inner shaft, and thus of the 
filament assembly, can be fixed by tightening a grub screw 
(accessible through a slot in the probe body) in a steel 
ring (not shown) around the inner shaft. The gap between 
the inner and outer shaft is sealed by the main vacuum seal 
assembly (5) which maintains the ion source vacuum during 
probe operation. The gas line (6) can be used to introduce 
the CI reagent gas into the ion chamber. The reagent gas 
exits through a hole in the ceramic feed-through (7) 
sweeping the filament tip. For the work described in this 
thesis the reagent gas was introduced into the ion chamber 
via the GC column inlet (Section 1.3) so the reagent gas 
inlet line of the probe was blocked off using a standard 
Swagelok connector and a short length of metal rod. The BNC 
connector (8) is used to deliver an electric current to the 
filament which is earthed to one side of the probe body_ 
The probe is operated as folloWs: 
A drop of sample solution is applied to the tip of the 
filament using a microlitre syringe and the solvent is 
allowed to evaporate. The filament assembly is then 
retracted inside the outer shaft by moving the probe handle 
downwards. The probe handle is locked in the retracted 
position by slightly rotating the handle into a cut-out (not 
shown) in the probe body - this prevents the probe extending 
prematurely when exposed to the ion source vacuum. The 
probe is then inserted through the mass spectrometer's 
solids probe insertion lock into the ion source and the 
filament is moved into the ion chamber by releasing the 
probe handle and sliding the handle forward. 
123 
5.4.3 Solid Probe Insertion Lock 
The HP5982A solid probe insertion lock has an internal 
diameter of only 6.35 rom which is too narrow to admit the 
12.7 rom diameter outer shaft of the Vacumetrics DCI probe. 
This lock was replaced with a Con Vac solid probe insertion 
lock (Consolidated Instruments Corp., Baltimore Md). The 
rough-out 'port of the Con Vac lock will accept different 
internal diameter probe entrance adaptors which are screwed 
into position and sealed by an a-ring. A 6.35 rom adaptor 
was fitted to this port to admit the HP5982A direct 
insertion probe to the ion source and this was replaced when 
appropriate with a 12.7 rom adaptor to admit the DCI probe. 
The distance from the ion source housing to the entry port 
of the new lock was identical with that for the existing 
lock - one section of the lock was rebuilt to achieve this. 
The conventional solids probe was therefore correctly 
positioned in the ion source with the 6.35 rom entrance 
adaptor. The length of the DCI,probe required the 12.7 rom 
adaptor to be shortened from its original 76.2 rom to 46.5 rom 
to position the probe's outer shaft when inserted up to the 
hilt correctly near the ion source DIP s (part 9 Figure 
34). 
5.4.4 Ion Source Modifications 
The HP5982A dual ion source has been described in 
Section 1.2. The following modifications to the ion source 
were made to allow the tip of the DCI probe filament to 
enter the CI ion chamber. 
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1. The hole in the gold-plated heater shroud (part 1, 
Figure 33) through which the existing solids probe passes 
before entering the DIP sleeve (part 9, Figure 34) was 
enlarged from 15 mm to 18 mm diameter to accommodate the 
outer shaft of the DCI probe. The shroud was replated after 
enlarging the hole. It was considered undesirable to modify 
the existing shroud but a replacement could not be purchased 
or constructed. In addition to the source heater the shroud 
also contains two magnets which collimate the electron beam 
in the ion chamber. The instrument manufacturer was 
consulted before enlarging the shroud hole to determine 
whether this modification would distort the magnetic field 
produced by the magnets. 
2. A problem inherent in the 5982A source design is the 
difficulty of ensuring that the probe entrance in the source 
block is in line with the DIP housing; this alignment 
changes as the copper a-ring flange seal is compressed. The 
original DIP sleeve was designed to guide the 6.35 mm probe 
into place even if the alignment was not perfect, and to 
seal the source ion chamber under CI conditions. The 
alignment problem proved to be more critical with the 
12.7 mm DCI probe, because the throat of the original sleeve 
was too narrow to accept the end of the probe and provide 
the necessary alignment. The new DIP sleeve, constructed of 
19 mm AF hexagonal stainless steel, had a wider bore which 
guided the 12.7 mm probe into position. 
3. The ~xisting plunger body (referred to as the plunger) 
had a 1.3 mm diameter DIP inlet hole which was too narrow to 
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admit the DCI probe filament tip. A new plunger body was 
constructed with external dimensions identical to those of 
the existing plunger and with a DIP inlet hole of 3.81 mm 
diameter. The new plunger was machined from stainless steel 
round bar. The fabrication of the mask for the electron 
entrance slit in the existing plunger could not be 
duplicated. The mask containing this slit for the new 
plunger was formed by cutting a rectangular aperture in a 
disc of stainless steel shim with a punch made for the 
purpose and fitting this disc into a stepped circle having a 
hole at its centre in the plunger wall. The disc was held 
in position with a circlip. 
4. The DIP sample inlet hole in the spacer (part 15, Figure 
35) was enlarged from 1.3 mm to 3.81 rom diameter to 
accommodate the DCI probe filament. A new spacer was not 
fabricated because the existing spacer could be readily 
replaced if necessary. 
5.4.5 Initial Probe Set-up 
The length of probe extension was adjusted initially 
with the ion source removed, to position the tip of the 
lament in the centre of the CI ion chamber. The DCI probe 
was inserted through the solids probe insertion lock up to 
the hilt and the filament was extended. A sight was taken 
down the interior of the ion source housing towards the 
quadrupole mass analyser and the length of probe extension 
was adjusted to position the tip of the filament in the 
centre of the ion optics axis. This position corresponds to 
the centre of the CI ion chamber. The grub screw in the 
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probe handle (Section 5.4.2) was then tightened to fix this 
length as the maximum possible extension of the probe. 
The probe was withdrawn from the insertion lock and the 
ion source was replaced. 
A glass guide, supplied by Vacumetrics, was used to 
align the filament with the probe axis on each occasion and 
just before the probe was inserted into the ion source. The 
filament is easily bent while being loaded with sample and 
is likely to be damaged inside the source if not aligned 
correctly; use of this alignment guide immediately before 
inserting the probe into the mass spectrometer is essential. 
5.5 Evaluation of Modifications 
The effect of the modifications which have just been 
described on the existing sensitivity of the mass 
spectrometer was assessed as follows: 
In EI mode replicate injections of a dilute solution of 
methyl stearate were made into the gas chromatograph while 
the mass spectrometer was set to monitor the intensity of 
the molecular ion of this compound (m/z 298). In CI mode, 
with ammonia reagent gas, replicate injections of a dilute 
solution of benztropine (Section 3.1) were made while 
monitoring the (M+l)+ ion (m/z 308). In both cases the ion 
intensities, measured as peak heights on a chart recorder, 
were averaged and compared with ion intensit measured 
under identical conditions before the ion source 
modifications were made. 
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The results showed that the instrument modifications 
caused no significant change in sensitivity in either EI or 
CI mode. 
The first sample to be examined using the DCI probe was 
the amino acid creatine. This compound has previously been 
selected for use in optimising experimental parameters 
during DCI experiments132 . A 1 ~L aliquot of a freshly 
prepared aqueous solution of creatine (SOD ng ~L-l) was 
applied to the probe filament by the method described 
earlier. The probe was inserted into the mass spectrometer 
operating under CI conditions with methane reagent gas. The 
probe tip was extended to the centre of the ion source and 
then rapidly heated by passing a current 2.9A through the 
filament. Spectra were recorded repetitively at the maximum 
scan rate of 325 amu/second immediately after probe 
insertion. The "bestll spectrum of creatine obtained is 
presented in Figure 23. It shows a protonated molecular ion 
peak (M+l)+ (m/z 132), and a base peak corresponding to the 
protonated cyclic lactone creatinine (m/z 114). 
100 114 
132 
100 200 
m/z 
Figure 23. DCI mass spectrum of creatine 
128 
5.6 In-Beam Operating Parameters 
The appearance of an in-beam mass spectrum is very 
dependent on experimental conditions. Spectra recorded 
using non-metallic probes, where the temperature of the 
source block determines the heating rate of the probe tip, 
have a protonated molecular ion intensity which is very 
sensitive to changes in both the source temperature and the 
position of the probe tip relative to the electron beam 
axis. Higher source temperatures have been reported to give 
a better relative abundance of this ion132 ,139. The optimal 
position for the probe tip has been found to be on139 , and 
2.5 mm froml17 ,132 the electron beam axis. Spectra obtained 
using metallic (directly heated) probes have been recorded 
with the source temperature at normal135 and at lower-than 
normal138 ,15l temperatures. The probe tip has been 
positioned directly in the electron beam124 in DEI 
experiments, and at various distances from 
it120 ,135,15l,143, including at. the boundary of the 
ionisation chamber138 , in DCI experiments. In the latter 
case centering of the probe tip in the source was found to 
cause increased sample decomposition. 
In this work DEI and DCI mass spectra were recorded at 
an ion source temperature of ca. 190°C. This temperature 
(the normal source operating temperature) allowed the 
instrument to be used without delay to also record spectra 
for samples admitted to the ion source via the conventional 
solids probe inlet or the GC inlet. 
The effect of the probe insertion distance during DCI 
and DEI operation was investigated as follows: 
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Spectra of creatine were recorded with the probe tip 0, 2.5, 
5, 7.5, 10 and 15 mm from the electron beam axis while the 
mass spectrometer was operating under CI conditions with 
methane reagent gas. The relative intensity of the 
protonated molecular ion was determined at each distance by 
measuring the ratio (M+H)+/(M-OH)+. The results, presented 
in Figure 24, show that the abundance of the (M+l)+ ion is 
strongly dependent upon the position of the probe tip in the 
ion source. The maximum value for the ratio of 
(M+H)+/(M-OH)+ was obtained when the probe tip was 2.5 mm 
from the electron beam axis. Spectra of creatine were also 
recorded with the probe tip 0, 2.5, 5, 7.5, 10 and 15 mm 
from the electron beam while the mass spectrometer was 
operating under EI conditions. An (M+l)+ ion was only 
observed when the probe tip was retracted 2.5 mm. 
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Figure 24. Variation of creatine (M+l)+/(M-17)+ ratio 
with distance from the ion beam axis to DCI probe tip. 
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5.7 Selected DEI and DCI Mass Spectra 
In-beam mass spectra for seven compounds of biological 
interest which have not previously been studied by DEI or 
DCI-MS are now presented. These spectra show that the 
in-beam technique is a viable alternative to other 
ionisation methods for obtaining molecular weight (and 
other) information for "difficult" samples. 
5.7.1 Barbitone and Amobarbitone 
These two compounds are derivatives of barbituric acid. 
Both have sedative and hypnotic properties and, like many 
barbiturates, they show no molecular ion in their 
conventional EI mass spectra152 , (although intense 
(M+l)+ ions are seen in their CI spectra153 ). 
DEI spectra for barbitone and amobarbitone are 
presented in Figure 25. The spectra resemble very closely 
the corresponding EI spectra152 but in addition show low 
intensity (M+l)+ ions. 
5.7.2 Meprobamate and Ephedrine 
Meprobamate is the prototype of the medicinal 
carbamates and is frequently employed as a sedative, 
anti-anxiety agent and muscle relaxant. Ephedrine, as the 
£-isomer, is a naturally occurring sympathomimetic amine 
that is used as a nasal decongestant and bronchodilator. 
The DEI spectra for meprobamate and ephedrine hydrochloride 
are presented in Figure 26. The EI spectra for both 
compounds152 show no ions characteristic of molecular weight 
but the DEI spectra both show (M+l)+ ion peaks. 
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Figure 25. DEI mass spectra of barbitone and amobarbitone. 
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Figure 26. DEI mass spectra of meprobamate and ephedrine 
hydrochloride. 
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5.7.3 Discorhabdin C and Discorhabdin A 
Two cytotoxic pigments named Discorhabdin C and 
Discorhabdin A (Figure 27) have recently been isolated from 
sponges of the genus Latrunculia du Bocage by the marine 
chemistry group at Canterbury University. These compounds, 
which are potential antitumour agents, were submitted for 
mass spectral analysis on the HP5982A. 
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Figure 27. Structures for Discorhabdin C and Discorhabdin A. 
The conventional EI spectrum of Discorhabdin C 
hydrochloride is presented in Figure 28. It shows an 
intense molecular ion cluster (m/z 461/463/465), and one 
significant fragment ion (m/z 147/149). All attempts to 
record conventional EI and CI spectra for Discorhabdin A 
hydrochloride were unsuccessful due to extensive 
decomposition of the sample as it was heated. The 
DCI/NH3 spectrum of Discorhabdin A hydrochloride, recorded 
over a limited mass range, is presented in Figure 29. The 
spectrum shows an (M+I)+ ion (m/z 416/418) and a fragment 
ion (m/z 384/386) corresponding to (MH-S)+. 
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Figure 28. EI mass spectrum of Discorhabdin C 
hydrochloride 
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Figure 29. Partial DCI(NH3) mass spectrum of 
Discorhabdin A hydrochloride 
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The utility of the in-beam technique in providing molecular 
weight information further illustrated by FAB-MS results 
for Discorhabdin A hydrochloride. The FAB spectrum of this 
compound, recorded in a glycerol matrix, is presented in 
Figure 30. It shows peaks (m/z 418/420) resulting from 
in-situ reduction of the sample154 , making 
a priori interpretation of the spectrum difficult. 
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Figure 30. FAB (argon) mass spectrum of Discorhabdin A 
hydrochloride in glycerol. (Courtesy of Dr P.T. Holland, 
Ruakura Plant Research Station, Hamilton N.Z.) 
5.7.4 Morphine-3-g1ucuronide 
This compound has been discussed in Section 2.4.1 • 
The ammonia CI mass spectrum of the underivatised conjugate, 
presented in Figure 31, shows no ion characteristic of 
molecular weight. The two major peaks seen {m/z 286,303} 
correspond to the protonated aglycon (Agly + l)+ and 
(Agly + NH4)+ respectively. The DCI/NH3 spectrum of 
morphine-3-g1ucuronide, presented in Figure 32, shows the 
(M+l)+ ion (m/z 462). 
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Figure 31. CI (NH3) mass spectrum of morphine-3-
glucuronide 
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Figure 32. DCI (NH3) mass spectrum of morphine-3-
glucuronide 
137 
5.8 ion 
A Hewlett Packard 5982A GCMS has been successfully 
modified to allow it to be used to record in-beam mass 
spectra with a commercially available DCI probe. 
6.1 General 
CHAPTER 6 
EXPERIMENTAL METHODS 
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Infrared spectra were recorded on a Shimadzu IR-27G 
spectrophotometer for liquid films and nujol mulls. 
lH n.m.r. spectra were obtained in deuterochloroform solvent 
with tetramethylsilane as an internal reference on a Varian 
T60 spectrometer. All chemical shifts are expressed as 
parts per million (ppm) downf ld from TMS and are quoted as 
position (0), multiplicity (s = singlet, d doublet, 
t triplet, q = quartet, m 
integral. 
multiplet) and relative 
Microanalyses were carried out by Professor A.D. 
Campbell and associates, University of Otago. 
Melting points were determined in open capillaries and 
are uncorrected. 
Weighings for standard solutions were performed on a 
Cahn model G electrobalance. 
Yields reported for preparative procedures are those 
for the final purified product obtained after 
recrystallisation. 
6.1.1 Reagents 
Lithium aluminium deuteride (Merck) had an isotopic 
purity better than 98%. N,O-bis(trimethylsilyl)-acetamide 
and N,O-bis(trimethylsilyl)trifluoroacetamide (both Pierce 
Chemical Co., Rockford, Ill.) were analytical reagents. All 
solvents used for extractions were of analytical grade (AR) 
and were distilled twice in glass before being stored in 
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acid-washed glass jars with glass stoppers. All solvents 
used for preparative procedures were analytical grade or 
were purified (and dried when necessary) according to 
standard procedures155 ,156. "Ether" refers to diethylether. 
All drugs were supplied by the Chemistry Division of the 
Department of Scientific and Industrial Research (D.S.I.R.) 
or by the Department of Nephrology or the Department of 
Anaesthetics, Christchurch Hospital. 
6.1.2 Biological Material 
Post-mortem blood and post-mortem liver were supplied 
by the Chemistry Division of D.S.I.R. Out-dated plasma was 
supplied by the Blood Bank, Christchurch Hospital. All 
biofluid and tissue samples were stored frozen until needed. 
6.1.3 Glassware 
All glassware was initially cleaned by soaking in a 
chromic acid bath (70 mL saturated sodium dichromate 
solution and 2 L of concentrated sulphuric acid157 ) for 
several hours and subsequently rinsed thoroughly several 
times with hot water before being drained and oven dried. 
All glassware used for drug extraction procedures, including 
Reacti-vials, was silanised by soaking overnight in a 
solution of dimethyldichlorosilane in toluene (1:20) 
followed by a methanol wash. After use glassware used for 
extraction procedures was soaked in boiling "Decon 90" 
(Decon Laboratories Ltd., Hove, England) for about 5 h, 
thoroughly rinsed with distilled water and oven dried before 
being resilanised. 
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6.1.4 Instrumentation 
The HP5982A GCMS used for this work has been described 
in Sections 1.2 and 1.3. The gas chromatograph was fitted 
with a 30 m x 0.32 mm i.d. fused silica BP-l capillary 
column (SGE Pty. Vict. Australia). Helium was used as the 
carrier gas and the flow rate through the column was 3 mL 
min-I. The temperature of the transfer oven was 250oC. The 
mass spectrometer ion source was operated in EI mode with an 
ionising energy of 50 eVe In CI mode the reagent gas 
pressure was optimised for the particular reagent gas used. 
The ion source temperature was ca. 190oC. Morphine analyses 
were performed using an OCI-3 on-column injector (SGE Pty.). 
Injections (1 ~L) were made at an oven temperature of l20 o C; 
after elution of the volatiles the oven temperature was 
increased rapidly to 280oC, giving a retention time for 
bis(trimethylsilyl)morphine of about 8 min. At the 
completion of each run the oven temperature was held at 
3000 C for 5 min. Benztropine and atropine analyses were 
both performed using a split/splitless injector (Chromalytic 
Technology Vict. 3150 Australia) operated in the split mode 
with a split ratio of 10:1. Injections (1 ~L) were made at 
an oven temperature of 230oC, giving a retention time for 
benztropine of about 2 min. and for atropine of 3 min. 
6.1.5 Mass Spectra 
Mass spectra were recorded using a Datagraph 5-154 
Recording Oscillograph (Bell and Howell, Pasadena, Ca.) 
connected to the GCMS. Ion intensities were determined by 
measuring peak heights with a ruler from the recorder paper. 
Mass spectra were normalised before being plotted. 
6.2 Experimental Section Relating to Chapter 2 
6.2.1 Preparative procedures 
Morphine and N-tri~~uteriomethylnormorphine 
The crude compounds 34 were purified by repeated 
recrystallisation from methanol:water followed by 
sUblimation under vacuum. 
Methyl(tetra-O-acetyl-S-D-glucopyranuronate) 
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Glucuronolactone (8.8 g) was treated with sodium 
methoxide and then acetic anhydride using the acid-catalysed 
acetylation procedure of Bollenback et a1 36 to give a white 
solid which was recrystallised from ethanol. Yield: 5.08 9 
(27%); m.p. 176-1770 (lit. 36 176.5-1780 ). 
M.s (CI/DIP ammonia), m/z: 394(M+NH4+, 100%), 317 (53), 
257(41). 
Methyl(tri-O-acetyl-a-D-glucopyranosyl bromide)-uronate 
Methyl (tetra-O-acetyl-S-D-glucopyranuronate) (2.5 g) was 
treated with 30% hydrobromic acid in acetic acid (10 mL) 
using the method of Bollenback et a1 36 to give a white solid 
which was recrystallised from ethanol. Yield: 1.65 9 (62%); 
m.p. 105-1060 (lit. 36 106-1070 ). 
M.s (CI/DIP ammonia), m/z: 416/414 (M+NH4+, 71/100%), 
317(28), 257(31). 
Morphine-(3S-D-glucopyranosyl)-uronate 
Morphine (0.10 g) was condensed with methyl-
(tri-O-acetyl-a-D-glucopyranosyl bromide}-uronate (O.lO g) 
using the method of Berrang et a1 35 . The crude product was 
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recrystallised twice from methanol. Yield: 40.2 mg (23%); 
m.p. 240-24l0 C(dec.) (lit. 35 240-242 0 (dec)i lH n.m.r. : 
Satisfactory spectra could not be obtained; I.R. (KBr): 
vmax = 3610, 1633, 1503 and 14.56 em-I; M.s.(EI/DIP, as 
penta-trimethylsilyl derivative), m/z: 821 (partial spectrum 
only). 
6.2.2 Preparation of Calibration Standards 
Methanol stock solutions of DO- and D3-morphine were 
prepared in silanised volumetric flasks according to the 
scheme in Table 26. From these stock solutions standard 
mixtures of the following ratios were made up to 50 mL in 
silanised volumetric flasks using methanol solvent: 4:1 
DO:D3 (800 ~L and 200 ~L), 2:1 (666 ~L and 333 ~L), 1:1 
(500 ~L and 500 ~L, 1:2 (333 ~L and 666 ~L) and 1:4 
(200 ~L and 800 ~L), using a 200-1000 ~L adjustable 
micropipette. 
The required standard mixtures (100 ~L) were added to 
drug free plasma (1 mL), thoroughly mixed and left to stand 
for lh before extraction and derivatisation using the method 
for unchanged morphine (Section 6.2.4). 
Solution concn. Mass of morphine Final volume 
(ng ~L-l) (mg) (mL) 
10 0.5000 50 
30 1.500 50 
100 5.000 50 
200 5.000 25 
Table 26. Scheme for preparing morphine standard solutions 
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6.2.3 Determination of Solvent Extraction Efficiency 
An appropriate amount of DO-morphine was added to 
aliquots (1 mL) of drug-free plasma. The spiked samples 
were thoroughly mixed, left to stand for 1 h and then 
extracted according to the procedure for unchanged morphine 
(Section 6.2.4) but with the following change: D3-morphine 
was added to the dry residue just prior to derivatisation. 
6.2.4 Extraction of Morphine from Serum and Plasma 
(a) Unchanged Morphine 
An appropriate amount of D3-morphine was added to serum 
(or plasma) (1 mL) in a 10 mL silanised-glass centrifuge 
tube having a ground glass stopper, thoroughly mixed and 
left to stand for 1 h. The serum (or plasma) was mixed with 
acetone (6 mL), centrifuged for 5 min, the organic layer 
transferred to a clean 10 mL centrifuge tube and the acetone 
evaporated at 70-80oC under nitrogen. The dry residue was 
taken up in 0.01 M hydrochloric acid (1 mL) and washed with 
benzene (2 x 4 mL). The aqueous phase was adjusted to pH 
8-9 by addition of 1 M sodium hydroxide, buffered to pH 8.9 
with borate buffer (1 mL) and extracted twice with isopropyl 
alcohol-dichloroethane (3:10 v/v) on a vortex mixer. The 
combined organic phase was reduced in volume, transferred to 
a 1 mL Reacti-vial (Pierce Chemical Co., Rockford, Ill.) and 
evaporated to dryness at 70-80oC under nitrogen. The 
residue was reacted with bis(trimethylsilyl) acetamide or 
bis(trimethylsllyl)trifluoroacetamide (50 ~L) in a sealed 
vial for 1 h at 60oC, and the resulting mixture used 
directly for GCMS analysis. 
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(b) Total Morphine 
An appropriate amount of D3-morphine was added to serum 
(or plasma) (I mL) in a 10 mL silanised glass centrifuge 
tube having a ground glass stopper, thoroughly mi and 
left to stand for 1 h. The serum (or plasma) was bu red 
at pH 5.0 with ca. 0.2 M acetate buffer (I mL), 2000 shman 
Units of S-glucuronidase (Sigma G-0750) added and the 
solution incubated in a water bath at 370C for 24h. The 
procedure for unchanged morphine was then followed. 
6.3 Experimental Section Relating to Chapter 3 
6.3.1 Preparative procedures 
Bromodiphenylmethane 
Benzhydrol (16.80 g) was treated with phosphorus 
tribromide (2 mL) using the method of Claisan76 to give a 
wh solid which was purified by vacuum distillation (0.5 
rom,1200C). Yield: 16.0 g (80%); m.p. 42-43 0C 
76 43-450C). 
Benztropine hydrobromide 
Tropine (5.27 g) was reacted with bromodiphenylmethane 
(la g) using the method of Weijlard75 . Benztropine was 
isolated as its hydrobromide and recrystallised from 
ethanol. Yield: 4.80 g (33%); m.p. 258.5-260o C 
75 250-2510C). 
Benztropine base 
Benztropine hydrobromide (4.60 g) was dissolved in 
water (20 mL), the solution was basified with sodium 
145 
carbonate and then extracted with chloroform (4 x 50 mL). 
The combined chloroform extracts were dried over magnesium 
sulphate, filtered (Whatman phase separating paper) and the 
solvent removed under vacuum to give a pale yellow viscous 
oil. Yield: 3.41 g (94%)i IH n.m.r. (CDC13) 1.75-2.15, m, 
8H, ring CH2i 2.22, s, 3H, CH3i 2.90-3.40, m, 2H, CHNCH; 
3.40-3.70, m, IH, HCO; 5.38, s, IH, OCH; 7.25, m, 10H, 
aromatic Hi M.s. (CI/DIP ammonia), M/z: 308 (M+H+, 100%), 
167 (38),140 (14),124 (11), 110 (40). 
N-(2,2,2-trichloroethoxycarbonyl)-norbenztropine 
To a mixture of benztropine base (3.23 g) and potassium 
carbonate (0.05 g) in refluxing benzene (25 mL) was added 
2,2,2-trichloroethylchloroformate (1.6 mL) dropwise over 0.5 
h. Reflux was then continued for a further 2.5 h. The 
solution was allowed to cool, washed twice with sodium 
hydroxide (1M), once with water and dried over magnesium 
sulfate. After filtering, the solvent was removed under 
vacuum to leave a white solid which on trituration with 
pentane:dichloromethane gave white crystals. Yield: 1.44 g 
(29%)i m.p. 121-122oCi (Found: C, 59.0; H, 5.2; N, 2.8; Cl, 
22.7. C23H24N03C13 requires C, 59.1; H, 5.1; N, 2.9; Cl, 
22.5%); IH n.m.r. (CDC13) 1.70-2.40, m, 8H, ring CH2; 
3.55-3.90, m, IH, HCO; 4.15-4.60, broad signal, 2H, CHNCHi 
4.60-4.95, m, 2H, COOCH2i 5.45, s, IH, OCHi 7.28, m, 10H, 
aromatic Hi M.s.(CI/DIP ammonia), m/z: 470/468, (M+H+, 
18/16%), 308(34),293(26),182(11),167(100). 
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N-Trideuteriomethylnorbenztropine hydrobromide 
A solution of N-(2,2,2-trichloroethoxycarbonyl)-
norben (0.25 g) in dry tetrahydrofuran (10 mL) was 
added dropwise to a stirred slurry of lithium aluminium 
deuteride (0.225 g) and tetrahydrofuran (40 mL) and the 
reaction mixture was refluxed for 74 h. After cooling the 
reaction was quenched by the cautious addition several 
drops of sodium sulphate solution and filtered. 
Removal of solvent under vacuum gave a pa 
syrup which was ssolved in ether (10 mL) and 
40% hydrobromic acid (0.1 mL). The mixture was 
vigorously and allowed to stand for 1 h at room 
yellow viscous 
with 
The resulting white precipitate was removed by filtration 
and recrystallised from water. Yield: 0.085 g (41%); m.p. 
259-260 o C. 
N-Trideuteriomethylnorbenztropine base 
N-Trideuteriomethylnorbenztropine hydrobromide 
(0.060 g) was dissolved in water (5 mL), the solution was 
basified with sodium carbonate and then extracted with 
chloroform (4 x 5 mL). The combined chloroform extracts 
were dried over magnesium sulphate, filtered (Whatman phase 
separating paper) and the solvent removed under vacuum to 
give a pale yellow viscous oil. Yield: 0.042 (88%), IH 
n.m.r. (CDC13) 1.75-2.28, m, 8H, ring CH2i 2.90-3.40, m, 
2H, CHNCHi 3.40-3.70, m, IH, HCOi 5.37, s, IH, OCH; 7.26, m, 
10H, aromatic Hi M.s. {CI/DIP ammonia), m/z: 311 (M+H+, 
~OO%), 167(34). 
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6.3.2 Preparation of Calibration Standards 
Methanol stock solutions of DO- and D3-benztropine were 
prepared by weighing 2.500 mg of DO- or D3-benztropine into 
a silanised volumetric flask (50 mL) and making up to the 
mark with methanol. From these stock solutions standard 
mi~tures of the following ratios were made up to 50 mL in 
silanised volumetric flasks using methanol solvent: 4:1 
DO:D3 (800 ~L and 200 ~L), 2:1 (666 ~L and 333 ~L), 1:1 
(500 ~L and 500 ~L, 1:2 (333 ~L and 666 ~L) and 1:4 
(200 ~L and 800 ~L), using a 200-1000 ~L adjustable 
micropipette. 
The required standard mixtures (100 ~L) were added to 
drug free blood (1 mL), thoroughly mixed and left to stand 
for lh before extraction using the method for benztropine. 
6.3.3 Determination of Solvent Extraction Efficiency 
(a) Blood 
An appropriate amount of DO-benztropine was added to 
aliquots (1 mL) of drug-free blood. The spiked samples were 
thoroughly mixed, left to stand for 1 h and then extracted 
according to the procedure for benztropine in blood. 
(Section 6.3.4) but with the following change: 
D3-benztropine was added just prior to evaporation of the 
organic solvent. 
(b) Liver 
An appropriate amount of DO-benztropine was added to 
samples of homogenised liver. The spiked samples were then 
extracted according to the procedure for benztropine in 
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liver (Section 6.3.5) but with the following change: 
D3-benztropine was added just prior to evaporation of the 
organic solvent. 
6.3.4 Extraction of Benztropine from Post-mortem Blood 
An appropriate amount of D3-benztropine hyrobromide was 
added to post-mortem blood (1 mL) in a 10 mL silanised glass 
centrifuge tube having a ground glass stopper, thoroughly 
mixed and left to stand for 1 h. The blood was made 
alkaline (pH 11-12) with 0.5 M sodium hydroxide (360 ~L) and 
extracted twice with l-chlorobutane (2 x 5 mL) on a vortex 
mixer for 2 min. The combined organic phase was reduced in 
volume to 2 mL and extracted into 0.05 M suphuric acid 
(1 mL) in the same manner as before. The upper organic 
phase was discarded and the aqueous phase washed with 1 mL 
of extraction solvent before re-alkini on with 0.5 M 
sodium hydroxide (220 ~L). The extraction was then repeated 
as before with 5 mL of extraction solvent. The solvent was 
evaporated to dryness at 40-50o C under nitrogen and the 
residue reconstituted in ethanol (50 ~). The centrifuge 
tube was stoppered and the lower portion of the tube heated 
to 40-50oC in a hot block for several minutes to reflux the 
ethanol and wash down the inside of the tube. The sample 
was cooled and used directly for GCMS analysis. 
6.3.5 Extraction of Benztropine from Post-mortem Liver 
Liver (10 g) was blended with Tris base (40 mL) and 
crystalline subtilisin (0.2 g) in a Waring electric blender. 
The resulting suspension was transferred to a 100 mL conical 
flask, covered with a watch glass and heated with stirring 
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at 50-60o C for 1 h. An aliquot (1 mL) of the cooled liver 
digest was then extracted with l-chlorobutane using the 
procedure for post-mortem blood. 
6.4 Experimental Section Relating to Chapter 4 
6.4.1 Preparative Procedures 
N-Ethoxycarbonylnortropine 
Tropine (2.50 g) was treated with ethylchloroformate 
(20 mL) using the method of Fung and DeGraw9S . The crude 
product was recrystallised from ether to give a white solid. 
Yield: 1.SO g (51%): m.p. 72-75 0 C (lit. 96 74-7S; I.R. 
(nujol): v max 3420 (OH), 16S0 cm- l (C=O); lH n.m.r. (CDC13) 
1.35 1.75, m, 3H, CH3; 1.75-2.45, m, SH, ring CH2i 
4.0-4.90, m, 5H, COOCH2, CHNCH, HCO; M.s. (CI/DIP ammonia), 
m/z: 200 (M + H+,lOO%). 
N-Trideuteriomethylnortropine. 
N-Ethoxycarbonylnortropine (1.76 g) was reduced with 
lithium aluminium deuteride using the method of Fung and 
DeGraw 9S to give a pale yellow viscous oil. Yield: 0.73 g 
(57%); I.R. (nujol): vmax = 3320, (OH), 2200, 2070 
cm- l (C-D); lH n.m.r. (CDC13): 1.40-2.35, m, SH, ring CB2; 
2.90-3.40, broad signal, 2H, CHNCH; 3.90-4.lS, m, IH, BCD; 
M.s. (CI/DIP ammonia), m/z: 145 (M+B+, 100%). 
Tropic acid. 
Phenylacetic acid (19.75 g) was reacted with magnesium 
and isopropylchloride to form the corresponding Grignard 
derivative, which was then treated with formaldehyde and 
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hydrolysed to tropic acid, all by the method of Blicke99 . 
The crude product was recrystallised from benzene. Yield: 
12.58g (52%); m.p. 114-115 0 (lit. 99 116-117); 
IH n.m.r. (D6DMSO/CDC13): 3.40-4.20, m, 3H, CH, CH2i 7.30, 
s, 5H, aromatic. 
Acetyltropyl chloride 
Tropic acid (3.0 g) was treated with acetyl chloride 
and then thionyl chloride using the method of Toomey and 
RiegellOO . The acetyltropyl chloride was used immediately. 
Yield: 2.90 g (66%); 
IH n.m.r. (D6DMSO/CDC13i 1.95, s, CH3; 3.60-4.95, 3H, 
CH,CH2; 7.32, s, 5H, aromatic. 
N-Trideuteriomethylnoratropine. 
N-Trideuteriomethylnortropine (0.70 g) was reacted with 
acetyltropyl chloride (1.40 g) using the method of Fung and 
DeGraw98 to give a white solid which was recrystallised from 
acetone. Yield: 0.75 g (53%); m.p. 106-108oC 
(lit. 98 105-108); I.R. (Nujol): vmax = 3500, 3320 (OR), 
2200, 2070, 2050 cm- l ; lR n.m.r. (CDC13): 1.50-2.30, m, 8R, 
ring CH2i 2.60-3.20, broad signal, 3R, OH, CHNCR; 4.90-5.10, 
m, IH, RCO; 7.30, s, 5H, aromatic H. 
6.4.2 Preparation of Calibration Standards 
Stock solutions of DO- and D3-atropine were prepared by 
weighing 0.500 mg of DO or D3-atropine into a silanised 
volumetric flask (10 mL) and making up to the mark with 
methanol. From these stock solutions std mixtures of the 
following ratios were made up to 5 mL in silanised 
151 
volumetric flasks using methanol solvent: 4:1 DO:D3 (800 ~L 
and 200 ~L), 2:1 (666 ~L and 333 ~L), 1:1 (500 ~L and 
500 ~L, 1:2 (333 ~L and 666 ~L) and 1:4 (200 ~L and 
800 ~L), using a 200-1000 ~L adjustable micropipette. 
The std mixtures were used directly as calibration 
standards. 
6.4.3 Preparation of Aqueous Plant Extract 
The preparation of the aqueous plant extract is 
described in Section 4.6. 
6.4.4 Extraction of Aqueous Plant Extract 
An appropriate amount of D3-atropine was added to the 
aqueous plant extract (1 mL) in a 10 mL silanised glass 
centrifuge tube having a ground glass stopper and the tube 
shaken. The extract was made basic (9-10) with aqueous 
ammonia solution and extracted twice with chloroform. The 
combined organic phase was evaporated to dryness at 70-80o C 
under nitrogen and the residue reconstituted in ethanol (100 
~L). The centrifuge tube was stoppered and the lower 
portion of the tube heated to 40-50 oC in a hot block for 
several minutes to reflux the ethanol and wash down the 
inside of the tube. The sample was cooled and used directly 
for GCMS analysis. 
6.4.5 Soxhlet Extraction of Plant Material 
Dried plant material (2.50 g) was extracted in a 
soxhlet apparatus with a mixture of 0.880 ammonia (60 mL), 
ethanol (120 mL) and ether (960 mL) for 24 h. The extract 
was allowed to cool, and then was filtered into a 2 L 
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volumetric flask and made up to the mark with additional 
ether. An aliquot (1 mL) of the extract was placed in a 10 
mL silanised glass tube having a ground glass stopper, an 
appropriate amount of D3-atropine added, and the tube 
shaken. The organic phase was extracted into 0.05 M 
sulphuric acid (1 mL) and the organic phase discarded. The 
aqueous phase was made basic (pH 9-10) with aqueous ammonia 
solution and extracted twice with chloroform. The combined 
organic phase was evaporated to dryness at 70-80 0 under 
nitrogen and the residue reconstituted in ethanol (100 ~L). 
The centrifuge was stoppered and the lower portion of the 
tube heated to 40-50 0 C in a hot block for several minutes to 
reflux the ethanol and wash down the inside of the tube. 
The sample was cooled and used directly for GCMS analysis. 
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Appendix A 
The tuning voltage supplied by each channel of the 
MID to control 
following circuit. 
x Power 
supply 
y 
mass spectrometer is adjusted using the 
To MS 
(via timing 
logic circuit) 
The mass range covered by each potentiometer was reduced 
by inserting a 2 kilohmn resistor at "x" and a 500 ohm 
resistor at "yn. 
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Appendix B 
Note 1: 
Drugs absorbed from the gastrointestinal tract into 
the bloodstream are carried first in the portal circulation 
to the liver where they may be metabolised. Loss of drug 
from the bloodstream on passage through the liver is termed 
the first-pass effect. In some cases, the first-pass effect 
may result in virtually complete elimination of the original 
drug before it gains access to the general circulation. 
Note 2: 
Haemodialysis is a procedure for removing waste products 
of metabolism from the blood when renal function is inadequate 
or has failed completely. Blood from the patient is passed 
through an artificial membrane surrounded by a dialysis 
fluid (the dialysate), and returned to the patient. Waste 
products such as urea, creatinine and uric acid diffuse out 
of the blood, across the dialyser membrane and into the 
dialysate. An anticoagulant is required to prevent the 
blood from clotting. 
Note 3: 
Haemodialysis requires repeated, reliable vascular 
access. This used to be by means of an external artificial 
arteriovenous shunt (Figure 38). During dialysis, the shunt is 
disconnected and the ends joined to the appropriate parts of 
the dialyser. Such shunts tended to clot and gave the patient 
no freedom to immerse the limb in water. The commonest access 
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in use today is a subcutaneous arteriovenous fistula 
(Figure 39). The radial artery in the non-dominant arm is 
joined, usually side to side, with the vein at the wrist so 
that the vein back up the arm increases in size and develops 
a thicker wall. This enlarged artery-like vein can be 
needled to provide access to the bloodstream, first to 
withdraw blood and then to return it after it has passed 
through the dialyser. 
Figure 38. External arteriovenous 
shunt. 
Note 4: 
Figure ~~: Subcutaneous arteriovenous 
fistula. 
A drug that is secreted into the bile presented again 
to the intestine and may be reabsorbed and passed again to the 
liver. This cycle of events is termed enterohepatic 
recirculation. The effect of this cycle is to increase the 
persistance of the drug in the body and, providing the 
concentrations of the drug at its sites of action are 
suff ently high, to prolong its duration of action. 
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Appendix C 
The equation of the weighted regression line which 
minimises the sum of the squares of the residual differences 
between the observed y values and the y values predicted from 
the regression line is given by y = a + bx, where b is the 
best estimate of the slope, given by 
b = L:UV 
L:U2-
and the best estimate of the intercept is given by 
where 
and 
x 
a y - bx 
1 
w = s2 
Ewx 
Ew 
and y = L:wy 
Ew 
EUV = Ew(x-x)(y-y) = L:wxy - x yEw. 
